Key Takeaways Edwards Lifesciences' TMTT sales surged 44.8% in Q2 2026, driven by PASCAL, EVOQUE and SAPIEN M3.EW's TAVR sales grew 10.5% on a constant-currency basis, lifting 2026 growth guidance to 8-9%.EW's $2.9 billion cash balance supports investments and buybacks, but tariffs and FX pressure margins.
Edwards Lifesciences (EW - Free Report) sees Transcatheter Mitral and Tricuspid Therapies (“TMTT”) momentum, fueled by PASCAL, EVOQUE and SAPIEN M3, supported by clinical evidence and broader market access. The company’s Transcatheter Aortic Valve Replacement (“TAVR”) business continues to grow, with SAPIEN platform durability and evidence supporting earlier treatment of aortic stenosis. Its strong balance sheet boosts investments and share repurchases. Meanwhile, Edwards faces tariff uncertainty and adverse currency movements that could pressure margins and earnings.
Over the past year, this Zacks Rank #3 (Hold) stock has gained 15% compared with the 2% growth of the industry and the S&P 500 composite’s 16% return.
The renowned global medical device company has a market capitalization of $43.95 billion. EW’s earnings yield of 2.7% favorably compares to the industry’s negative 2.2% yield. In the trailing four quarters, Edwards delivered an average earnings surprise of 5.7%.
Let’s delve deeper.
Upsides for EW StockTMTT Portfolio Holds Potential: Edwards’ TMTT portfolio remains a major source of growth as the company scales repair and replacement therapies across mitral and tricuspid disease. Second-quarter 2026 TMTT sales were $195.9 million, up 44.8% on a constant-currency basis, with global mitral and tricuspid procedure growth remaining in the double digits. PASCAL, EVOQUE and SAPIEN M3 all contributed ahead of management’s expectations. PASCAL adoption continues to increase, supported by differentiated design and clinical outcomes. Real-world data showed sustained one-year safety and effectiveness for PASCAL PRECISION in more than 4,600 U.S. degenerative mitral regurgitation patients.
Edwards also received CE Mark for SAPIEN M3 RESILIA and broadened the European indication for SAPIEN M3 and SAPIEN M3 RESILIA to patients with mitral annular calcification. ENCIRCLE registry data also showed low 30-day mortality, near elimination of regurgitation and quality-of-life improvement in this population. The company expects these layered platforms to provide durable growth beyond the current launch phase as access broadens and centers gain experience.
Image Source: Zacks Investment Research
TAVR Looks Promising: Edwards’ TAVR franchise continues to benefit from the clinical and technology investments built around the SAPIEN platform. Second-quarter 2026 TAVR sales were about $1.3 billion and increased 10.5% on a constant-currency basis. Growth rates were similar in the United States and outside the United States, while average selling prices remained stable globally. Edwards also reported modest year-over-year competitive position gains in the United States and Europe.
The evidence base continues to support broader and earlier treatment. A seven-year PARTNER 3 subanalysis reinforced SAPIEN valve performance and durability, while a five-year EARLY TAVR analysis added evidence supporting intervention earlier in the aortic-stenosis disease pathway. Updated European guidelines are also shaping clinical discussion around proactive treatment, and Japan approved the asymptomatic indication in second-quarter 2026.
The next catalyst is the PROGRESS trial, which will evaluate whether certain moderate aortic-stenosis patients may benefit from earlier TAVR treatment. Following second-quarter performance, management raised 2026 TAVR constant-currency sales growth guidance to 8-9% from 7-9%.
Strong Solvency: Edwards ended second-quarter 2026 with about $2.9 billion in cash and cash equivalents, with roughly $600 million of debt, providing flexibility for investment and repurchases. About $1.5 billion remained under its repurchase authorization.
What Ails Edwards?Macro Concerns Weigh on Margins: Edwards’ global manufacturing and commercial footprint leaves results exposed to trade-policy changes, inflation and cross-border cost shifts. In its second-quarter 2026 filing, the company said increased U.S. tariffs and retaliatory tariffs could affect its business and that it is evaluating supply-chain, exemption and exclusion options to mitigate potential effects. The company cannot predict future tariff rates or whether mitigation will be sufficient. Current results also show sensitivity to external cost factors. Adjusted gross margin was 77.6% in second-quarter 2026, flat year over year, as lower manufacturing expenses offset foreign-exchange effects.
Foreign Exchange Remains a Margin Risk: Currency movements remain an important earnings variable because Edwards generates substantial sales and expenses outside the United States. Foreign exchange increased second-quarter 2026 reported sales by about $15 million but reduced adjusted gross margin by roughly 70 basis points versus the prior year. Management expects foreign exchange to reduce second-half sales by about $35 million if rates remain at current levels and now sees 2026 gross margin near the lower end of its 78%-79% range.
EW Stock Estimate TrendThe Zacks Consensus Estimate for Edwards’ 2026 earnings per share (EPS) has remained constant at $3.00 in the past 60 days.
The Zacks Consensus Estimate for the company’s 2026 revenues is pegged at $6.76 billion, suggesting an 11.4% improvement from the year-ago reported number.
Key PicksSome better-ranked stocks in the broader medical space are Phibro Animal Health (PAHC - Free Report) , IDEXX Laboratories (IDXX - Free Report) and Globus Medical (GMED - Free Report) .
Phibro Animal Health has an earnings yield of 9.3% compared with the industry’s 2.7%. Shares of the company have dropped 2.3% compared with the industry’s 26.8% decline over the past year. PAHC’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 18.4%.
PAHC sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
IDEXX Laboratories, carrying a Zacks Rank #2 (Buy), has an earnings yield of 2.7% against the industry’s negative 2.2% yield. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 5.7%. IDXX shares have plunged 12.7% against the industry’s 2% growth over the past year.
Globus Medical, carrying a Zacks Rank #2, has an earnings yield of 6.8% against the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED shares have rallied 26.1% compared with the industry’s 2% gain over the past year.
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced that the U.S. Food and Drug Administration (FDA) has approved its PASCAL Precision system for tricuspid valve repair. The system is indicated for improving quality of life and functional status in patients with symptomatic severe tricuspid regurgitation (TR) despite optimal medical therapy who are deemed at intermediate or greater risk for surgery and deemed appropriate for transcatheter edge-to-edge tr.
On October 21, 2026, we delve into the DCF analysis for Edwards Lifesciences Corp EW, a company that has shown a 17.3% increase in price over the past year but has a predictability rank of only 1 out of 5 stars. The current price stands at $88.29, raising questions about its valuation amidst mixed signals from different models.
DCF Earnings-based intrinsic value indicates a significant overvaluation with a margin of safety of -123.2% compared to the current price. DCF Free Cash Flow (FCF)-based intrinsic value also suggests overvaluation, standing at $26.39, with a margin of safety of -234.6%. GF Score™ of 95/100 suggests strong performance metrics, but the low predictability rank raises concerns about the reliability of the DCF inputs. What Is EW Worth? DCF Earnings-Based Model The DCF earnings-based model for Edwards Lifesciences Corp employs a two-stage approach to assess its intrinsic value. The first stage considers a growth phase where earnings per share (EPS) is expected to grow at a robust rate of 11.9% annually for the next ten years, followed by a terminal phase with a more conservative growth rate of 4% for the subsequent ten years.
Parameter Value Current EPS (TTM, excl. non-recurring) $2.37 10-Year Growth Rate 11.9% 10-Year Treasury Rate 5.12% Discount Rate (ceil(Treasury) + 6%) 12% Terminal Growth Rate 4% In the growth stage, the EPS grows at 11.9% per year for ten years, discounted at a rate of 12%. The terminal phase then assumes a 4% growth rate for the next ten years, also discounted at 12%. Here’s a summary of the calculations:
Stage Description Value Growth Stage (Years 1-10) EPS growing at 11.9%, discounted at 12% $23.57 Terminal Stage (Years 11-20) 4% terminal growth, discounted at 12% $15.98 Intrinsic Value Growth + Terminal $39.55 With the current price at $88.29, the intrinsic value of $39.55 indicates that the stock is significantly overvalued, presenting a margin of safety of -123.2%. It is important to note that GuruFocus uses EPS figures that exclude non-recurring items, as research shows that stock prices correlate more closely with earnings than with free cash flow. For further analysis, you can visit the EW DCF Calculator.
What Does the Free Cash Flow DCF Say? The free cash flow (FCF)-based intrinsic value for Edwards Lifesciences Corp is calculated at $26.39. This value also indicates significant overvaluation compared to the current price. The FCF model and the earnings-based DCF model disagree, with the FCF model suggesting a lower intrinsic value. The margin of safety here stands at -234.6%, reinforcing the notion that the stock is overvalued.
How Does GF Value™ Compare to the DCF Models? Adding another layer to the analysis, the GF Value™ for Edwards Lifesciences Corp is calculated at $94.79, suggesting that the stock is undervalued by 6.9%. This proprietary measure takes into account historical trading multiples, past business growth, and future performance estimates. The divergence among the three models—DCF earnings, DCF FCF, and GF Value™—highlights the complexity of accurately valuing this stock. For more insights, check the GF Value™ page.
What Does EW's GF Score™ Tell Us? The GF Score™ is a comprehensive measure that evaluates a company's financial strength, profitability, growth potential, valuation, and momentum. Edwards Lifesciences Corp boasts a GF Score™ of 95/100, indicating strong performance across these metrics. However, the predictability rank of 1 out of 5 stars suggests that the DCF model may be less reliable for this stock, emphasizing the need for caution when interpreting its valuation.
Metric Rating GF Score™ 95/100 Financial Strength 7/10 Profitability 9/10 Growth 9/10 Valuation 9/10 Momentum 10/10 For more details, visit the EW stock page.
Key Assumptions and Limitations It is crucial to recognize that DCF models are highly sensitive to the assumptions made regarding growth rates and discount rates. Stocks with low predictability ratings, such as Edwards Lifesciences Corp, yield less reliable DCF estimates. The terminal growth rate of 4% is a simplifying assumption that may not reflect future market conditions accurately.
What This Means for Investors In synthesizing the insights from the DCF earnings model, the FCF model, and the GF Value™, a clear tension emerges. The earnings DCF and GF Value™ suggest significant overvaluation, while the FCF model provides a more conservative view. The guru ownership signal indicates that 14 gurus currently hold the stock, with 6 adding to their positions and 10 trimming theirs, while insiders have sold $27.7 million worth of shares over the past year. This mixed signal from guru activity, combined with the low predictability rank, suggests that investors should exercise caution. For a deeper dive into the valuation, explore the EW DCF Calculator.
Frequently Asked Questions What is EW's intrinsic value based on DCF?
Answer: earnings-based $39.55, FCF-based $26.39
Is EW overvalued or undervalued?
Answer: Based on the DCF models, EW is significantly overvalued, while GF Value™ suggests it is slightly undervalued.
How reliable is the DCF model for EW?
Answer: The DCF model's reliability is low, with a predictability rank of 1 out of 5 stars.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Disclosures
I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.
Birch Hill Investment Advisors LLC lowered its stake in Edwards Lifesciences Corporation (NYSE:EW – Free Report) by 1.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 723,022 shares of the medical research company’s stock after selling 12,355 shares during the quarter. Edwards Lifesciences comprises about 2.7% of Birch Hill Investment Advisors LLC’s portfolio, making the stock its 14th biggest holding. Birch Hill Investment Advisors LLC owned about 0.13% of Edwards Lifesciences worth $62,411,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Hanson & Doremus Investment Management purchased a new position in Edwards Lifesciences in the 1st quarter valued at approximately $25,000. MV Capital Management Inc. purchased a new position in shares of Edwards Lifesciences in the 4th quarter valued at about $26,000. RMG Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences during the first quarter worth approximately $26,000. Pin Oak Investment Advisors Inc. purchased a new position in Edwards Lifesciences in the second quarter worth approximately $26,000. Finally, GK Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at approximately $26,000. 79.46% of the stock is owned by hedge funds and other institutional investors.
Edwards Lifesciences Price Performance EW stock opened at $86.52 on Friday. The stock’s fifty day simple moving average is $88.44 and its 200-day simple moving average is $86.33. Edwards Lifesciences Corporation has a 52-week low of $72.67 and a 52-week high of $96.29. The stock has a market capitalization of $49.82 billion, a price-to-earnings ratio of 49.72, a price-to-earnings-growth ratio of 2.27 and a beta of 0.87. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06.
Edwards Lifesciences (NYSE:EW – Get Free Report) last released its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. The firm had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. Edwards Lifesciences’s revenue was up 13.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities research analysts expect that Edwards Lifesciences Corporation will post 3.00 EPS for the current year. Analyst Ratings Changes A number of research analysts have recently commented on the company. Barclays upgraded Edwards Lifesciences to a “strong-buy” rating in a report on Wednesday, October 7th. TD Cowen reissued a “buy” rating on shares of Edwards Lifesciences in a research report on Tuesday, July 21st. Citigroup reiterated a “buy” rating on shares of Edwards Lifesciences in a research note on Monday, October 5th. Truist Financial upped their price target on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a research report on Thursday, July 16th. Finally, Royal Bank Of Canada upped their target price on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a report on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $100.27.
View Our Latest Stock Analysis on EW
Insiders Place Their Bets In other news, VP Annette Brüls sold 2,644 shares of the company’s stock in a transaction on Friday, August 28th. The shares were sold at an average price of $89.98, for a total value of $237,907.12. Following the completion of the transaction, the vice president directly owned 17,984 shares in the company, valued at approximately $1,618,200.32. This represents a 12.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Andrew M. Dahl sold 544 shares of the stock in a transaction that occurred on Monday, August 31st. The shares were sold at an average price of $91.06, for a total value of $49,536.64. Following the transaction, the senior vice president owned 14,868 shares of the company’s stock, valued at approximately $1,353,880.08. This trade represents a 3.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 5,045 shares of company stock worth $451,596 in the last 90 days. 0.31% of the stock is owned by company insiders.
(Free Report)
Edwards Lifesciences Corporation is a medical technology company focused on therapies for structural heart disease and other cardiovascular conditions. The company develops and manufactures heart valve replacement and repair technologies, including transcatheter aortic valve replacement systems, surgical heart valves, transcatheter mitral and tricuspid therapies, and related delivery systems and accessories.
Founded in 1958 by engineer Miles “Lowell” Edwards, the company helped pioneer artificial heart valves and has played a significant role in the development of transcatheter valve replacement.
Read More Five stocks we like better than Edwards Lifesciences Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027 ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid Does the AI Selloff Put Alphabet’s Breakout in Doubt? Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW – Free Report).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
First Citizens Bank & Trust Co. bought a new stake in Edwards Lifesciences Corporation (NYSE:EW – Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 9,174 shares of the medical research company’s stock, valued at approximately $792,000.
Other hedge funds and other institutional investors have also made changes to their positions in the company. BlackRock Inc. purchased a new stake in Edwards Lifesciences during the 2nd quarter worth $5,318,092,000. Bank of New York Mellon Corp acquired a new stake in Edwards Lifesciences in the 2nd quarter valued at $1,274,082,000. Bank of America Corp DE purchased a new position in Edwards Lifesciences in the second quarter valued at about $605,397,000. Deutsche Bank AG purchased a new position in Edwards Lifesciences in the second quarter valued at about $516,552,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Edwards Lifesciences by 0.6% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,488,643 shares of the medical research company’s stock valued at $496,503,000 after purchasing an additional 30,495 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.
Insider Activity In other news, VP Daniel Lippis sold 619 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total transaction of $56,966.57. Following the completion of the sale, the vice president owned 40,034 shares of the company’s stock, valued at approximately $3,684,329.02. This trade represents a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 544 shares of Edwards Lifesciences stock in a transaction on Monday, August 31st. The stock was sold at an average price of $91.06, for a total transaction of $49,536.64. Following the completion of the sale, the senior vice president owned 14,868 shares of the company’s stock, valued at approximately $1,353,880.08. This trade represents a 3.53% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 5,045 shares of company stock worth $451,596. 0.31% of the stock is currently owned by insiders.
Wall Street Analysts Forecast Growth A number of brokerages have commented on EW. TD Cowen restated a “buy” rating on shares of Edwards Lifesciences in a research note on Tuesday, July 21st. Evercore reiterated an “outperform” rating and issued a $100.00 target price on shares of Edwards Lifesciences in a research note on Monday, July 6th. UBS Group reiterated a “buy” rating on shares of Edwards Lifesciences in a report on Thursday, October 8th. Mizuho boosted their price target on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th. Finally, Wall Street Zen raised Edwards Lifesciences from a “hold” rating to a “buy” rating in a research report on Saturday. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $100.27. View Our Latest Analysis on Edwards Lifesciences
Edwards Lifesciences Price Performance EW opened at $86.52 on Friday. The company has a fifty day simple moving average of $88.44 and a 200 day simple moving average of $86.33. The firm has a market cap of $49.82 billion, a price-to-earnings ratio of 49.72, a PEG ratio of 2.31 and a beta of 0.87. Edwards Lifesciences Corporation has a twelve month low of $72.67 and a twelve month high of $96.29. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06.
Edwards Lifesciences (NYSE:EW – Get Free Report) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The firm had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. During the same quarter in the previous year, the business posted $0.67 EPS. The firm’s revenue was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities research analysts expect that Edwards Lifesciences Corporation will post 3.00 EPS for the current fiscal year.
Edwards Lifesciences Profile (Free Report)
Edwards Lifesciences Corporation is a medical technology company focused on therapies for structural heart disease and other cardiovascular conditions. The company develops and manufactures heart valve replacement and repair technologies, including transcatheter aortic valve replacement systems, surgical heart valves, transcatheter mitral and tricuspid therapies, and related delivery systems and accessories.
Founded in 1958 by engineer Miles “Lowell” Edwards, the company helped pioneer artificial heart valves and has played a significant role in the development of transcatheter valve replacement.
See Also Five stocks we like better than Edwards Lifesciences Bank of America Stock Sell-Off Looks Like a Buying Opportunity AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff? GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
Assenagon Asset Management S.A. grew its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW – Free Report) by 50.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,719,271 shares of the medical research company’s stock after buying an additional 906,345 shares during the quarter. Assenagon Asset Management S.A. owned 0.47% of Edwards Lifesciences worth $234,727,000 at the end of the most recent reporting period.
Several other hedge funds have also recently made changes to their positions in EW. BlackRock Inc. bought a new position in Edwards Lifesciences during the second quarter valued at $5,318,092,000. Varma Mutual Pension Insurance Co purchased a new stake in shares of Edwards Lifesciences in the second quarter valued at $11,168,000. Conway Capital Management Inc. purchased a new stake in shares of Edwards Lifesciences in the second quarter valued at $954,000. Commerce Bank bought a new stake in shares of Edwards Lifesciences in the 2nd quarter worth about $3,121,000. Finally, Bank of America Corp DE bought a new stake in shares of Edwards Lifesciences in the 2nd quarter worth about $605,397,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of equities analysts recently commented on the stock. TD Cowen reaffirmed a “buy” rating on shares of Edwards Lifesciences in a research note on Tuesday, July 21st. Piper Sandler reiterated an “overweight” rating and set a $101.00 price target (up from $100.00) on shares of Edwards Lifesciences in a report on Friday, July 24th. BTIG Research reissued a “buy” rating and issued a $110.00 price objective on shares of Edwards Lifesciences in a research report on Friday, September 11th. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Friday, July 17th. Finally, Truist Financial increased their price target on Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “hold” rating in a report on Thursday, July 16th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $100.27.
Read Our Latest Analysis on EW
Insiders Place Their Bets
In other news, VP Daniel Lippis sold 619 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total transaction of $56,966.57. Following the transaction, the vice president directly owned 40,034 shares of the company’s stock, valued at approximately $3,684,329.02. This trade represents a 1.52% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 544 shares of the firm’s stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $91.06, for a total transaction of $49,536.64. Following the transaction, the senior vice president directly owned 14,868 shares in the company, valued at approximately $1,353,880.08. This trade represents a 3.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 5,045 shares of company stock worth $451,596 in the last three months. Corporate insiders own 0.31% of the company’s stock.
Shares of EW opened at $88.05 on Friday. The firm has a fifty day moving average price of $88.51 and a 200-day moving average price of $86.33. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $50.70 billion, a P/E ratio of 30.76, a P/E/G ratio of 2.27 and a beta of 0.87. Edwards Lifesciences Corporation has a 12-month low of $72.42 and a 12-month high of $96.29.
Edwards Lifesciences (NYSE:EW – Get Free Report) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The company had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. During the same quarter last year, the firm posted $0.67 EPS. The firm’s revenue was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities research analysts expect that Edwards Lifesciences Corporation will post 3.00 earnings per share for the current year.
Edwards Lifesciences Company Profile
(Free Report)
Edwards Lifesciences Corporation is a medical technology company focused on therapies for structural heart disease and other cardiovascular conditions. The company develops and manufactures heart valve replacement and repair technologies, including transcatheter aortic valve replacement systems, surgical heart valves, transcatheter mitral and tricuspid therapies, and related delivery systems and accessories.
Founded in 1958 by engineer Miles “Lowell” Edwards, the company helped pioneer artificial heart valves and has played a significant role in the development of transcatheter valve replacement.
See Also
Five stocks we like better than Edwards Lifesciences
ASML Can’t Keep Up With AI Demand—Why That’s a Good Thing
Enovix’s 100,000-Battery Drone Order Sets Up a Test of Its Production Plans
AMD’s Support Could Help Fermi Stock Overcome Its Biggest Hurdle
Beyond the GPU: Credo Paves the Next AI Data Superhighway
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
Elutia (NASDAQ:ELUT – Get Free Report) and Edwards Lifesciences (NYSE:EW – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, risk, valuation, institutional ownership, analyst recommendations and earnings.
Analyst Ratings This is a summary of current recommendations and price targets for Elutia and Edwards Lifesciences, as reported by MarketBeat.
Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Elutia 1 0 0 0 1.00 Edwards Lifesciences 0 5 16 1 2.82 Edwards Lifesciences has a consensus target price of $100.27, indicating a potential upside of 17.60%. Given Edwards Lifesciences’ stronger consensus rating and higher possible upside, analysts plainly believe Edwards Lifesciences is more favorable than Elutia.
Risk and Volatility Elutia has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500. Institutional & Insider Ownership 74.0% of Elutia shares are held by institutional investors. Comparatively, 79.5% of Edwards Lifesciences shares are held by institutional investors. 17.8% of Elutia shares are held by company insiders. Comparatively, 0.3% of Edwards Lifesciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Profitability This table compares Elutia and Edwards Lifesciences’ net margins, return on equity and return on assets.
Net Margins Return on Equity Return on Assets Elutia 426.93% -407.37% -47.08% Edwards Lifesciences 15.43% 15.68% 12.05% Valuation & Earnings This table compares Elutia and Edwards Lifesciences”s top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Elutia $12.14 million 3.00 $53.38 million $0.95 0.87 Edwards Lifesciences $6.51 billion 7.54 $1.07 billion $1.74 49.00 Edwards Lifesciences has higher revenue and earnings than Elutia. Elutia is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.
Summary Edwards Lifesciences beats Elutia on 13 of the 15 factors compared between the two stocks.
About Elutia (Get Free Report)
Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
(Get Free Report)
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient’s heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Receive News & Ratings for Elutia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elutia and related companies with MarketBeat.com's FREE daily email newsletter.
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended Sept. 30, 2026 after the market closes on Wednesday, Nov. 4, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at ir.edwards.com. About Edwards Lifescie.
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced that it will host an investor event in conjunction with the TCT annual scientific symposium in San Diego on Monday, Nov. 2, from 5:00 to 6:00 PM Pacific Time. The meeting will include a live Q&A session with physicians and members of the Edwards management team. A live webcast of the event will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived versio.
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced that the U.S. Food and Drug Administration (FDA) has approved the AUTUS Size-Adjustable Valve, a surgical pulmonary valve designed specifically for pediatric patients with congenital heart disease who require pulmonary valve replacement. For many pediatric patients, pulmonary valve replacement is not a one-time event. The AUTUS valve is the first FDA-approved surgical pulmonary valve designed for pediatric anatomy,.
On September 30, 2026, we delve into the DCF analysis for Edwards Lifesciences Corp EW, a company that has shown a mixed price performance recently, with a year-to-date increase of 3.3% and a one-year gain of 14.1%. However, the stock has faced some downward pressure, with a 1-week decline of 0.8% and a 1-month drop of 2.4%. Here are some key points to consider:
DCF Earnings-based intrinsic value of $39.55 compared to the current price of $88.08 (margin of safety: -122.7%) DCF Free Cash Flow-based intrinsic value of $26.39, indicating a significant overvaluation GF Score™ of 95/100 suggests strong fundamentals, but with a predictability rank of 1/5 stars, the reliability of the DCF inputs is questionable What Is EW Worth? DCF Earnings-Based Model The DCF earnings-based model for Edwards Lifesciences Corp utilizes a two-stage approach to estimate the intrinsic value of the stock. The first stage assumes a robust earnings growth rate of 11.9% for the next ten years, after which the growth rate is expected to slow to a terminal rate of 4% for the subsequent ten years. The discount rate applied is 12%, derived from the risk-free rate and equity risk premium.
Parameter Value Current EPS (TTM, excl. non-recurring) $2.37 10-Year Growth Rate 11.9% 10-Year Treasury Rate 5.22% Discount Rate (ceil(Treasury) + 6%) 12% Terminal Growth Rate 4% The calculation summary for the two-stage model is as follows:
Stage Description Value Growth Stage (Years 1-10) EPS growing at 11.9%, discounted at 12% $23.57 Terminal Stage (Years 11-20) 4% terminal growth, discounted at 12% $15.98 Intrinsic Value Growth + Terminal $39.55 When comparing the current price of $88.08 to the intrinsic value of $39.55, it is evident that the stock is significantly overvalued, with a margin of safety of -122.7%. GuruFocus emphasizes the use of EPS excluding non-recurring items, as research indicates that stock prices correlate more closely with earnings than with free cash flow. For further analysis, you can visit the EW DCF Calculator.
What Does the Free Cash Flow DCF Say? The Free Cash Flow (FCF)-based intrinsic value for Edwards Lifesciences Corp is calculated at $26.39. This figure diverges significantly from the earnings-based intrinsic value of $39.55, reinforcing the notion that the stock is overvalued. The margin of safety here is a staggering -233.8%, indicating that both DCF models suggest a similar conclusion regarding the stock's valuation.
How Does GF Value™ Compare to the DCF Models? In addition to the DCF analyses, the GF Value™ for Edwards Lifesciences Corp stands at $94.10, suggesting a 6.4% undervaluation. This proprietary measure from GuruFocus is derived from historical trading multiples, past business growth, and future performance estimates. The divergence among the three valuation models—DCF earnings, DCF FCF, and GF Value™—highlights the uncertainty surrounding the stock's true value. For more insights, visit the GF Value™ page.
What Does EW's GF Score™ Tell Us? The GF Score™ provides a comprehensive assessment of a company's financial health and growth potential. With a score of 95/100, Edwards Lifesciences Corp demonstrates strong fundamentals, but the low predictability rank of 1/5 stars indicates that the DCF model's reliability is compromised. Below is a summary of the GF Score™ metrics:
Metric Rating GF Score™ 95/100 Financial Strength 7/10 Profitability 9/10 Growth 9/10 Valuation 9/10 Momentum 10/10 Given the predictability rank of 1/5 stars, it is crucial to approach the DCF results with caution. For more details, visit the EW stock page.
Key Assumptions and Limitations It is important to note that DCF models are highly sensitive to the assumptions made regarding growth rates and discount rates. Stocks with low predictability ratings, such as Edwards Lifesciences Corp, tend to produce less reliable DCF estimates. The terminal growth rate of 4% is a simplifying assumption that may not accurately reflect future conditions.
What This Means for Investors In synthesizing the three valuation perspectives—DCF earnings, DCF FCF, and GF Value™—it becomes clear that there is a significant disagreement among the models. The DCF earnings and FCF models indicate that the stock is overvalued, while the GF Value™ suggests a slight undervaluation. The guru ownership signal is also noteworthy, with 14 gurus currently holding the stock, 6 of whom are adding to their positions while 10 are trimming. Additionally, insider activity shows net selling of $27.7M over the past 12 months, which may raise concerns about future performance. This divergence in signals underscores the need for caution when considering an investment in Edwards Lifesciences Corp. For a deeper dive into the valuation, check out the EW DCF Calculator.
Frequently Asked Questions What is EW's intrinsic value based on DCF?
Based on the DCF analysis, the earnings-based intrinsic value is $39.55, while the FCF-based intrinsic value is $26.39.
Is EW overvalued or undervalued?
Both the DCF models indicate that EW is significantly overvalued, while the GF Value™ suggests a slight undervaluation at $94.10.
How reliable is the DCF model for EW?
The DCF model's reliability for EW is questionable, given its low predictability rank of 1/5 stars.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Disclosures I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.
A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBHEdwards Lifesciences NYSE: EW outlined a strategy centered on structural heart disease, with Chief Executive Officer Bernard Zovighian highlighting five therapy areas that the company views as its principal growth platforms: transcatheter aortic valve replacement for aortic stenosis, PASCAL, EVOQUE, SAPIEN M3 and surgical therapies.
Zovighian said the company’s focus on structural heart disease provides “strategic clarity” in a large and growing market with significant unmet patient need. He said Edwards’ approximately 17,000 employees are driven by the company’s patient-focused mission, while its leadership team is concentrated on execution in structural heart disease.
Get Edwards Lifesciences alerts:
CMS Coverage Decision Expands TAVR Flexibility Beyond Biotech—3 Healthcare Stocks for Growth-Minded InvestorsA central topic of the discussion was the recent Centers for Medicare & Medicaid Services National Coverage Determination, or NCD, for TAVR. Zovighian characterized the decision as positive for patients, the field and Edwards, saying CMS determined that the therapy is “reasonable and necessary” following years of clinical evidence and physician experience.
He identified four major elements of the updated policy:
Greater flexibility in patient evaluation, including one required in-person physician visit rather than two. Greater flexibility during procedures, with one required operator rather than a mandatory surgeon and cardiologist both present in the room. Removal of hospital procedure-volume requirements to establish a TAVR program, while operator requirements remain in place. Coverage with evidence development for asymptomatic patients and a pathway for Medicare Administrative Contractor coverage of future FDA-approved indications. 3 Healthcare Pathbreakers With Long-Term TailwindsEdwards estimates there are roughly 1,100 cardiac surgery centers in the U.S., compared with about 850 existing TAVR centers. Zovighian said the gap represents a potential opportunity for some cardiac surgery centers to open TAVR programs, though he does not expect all of them to do so. He estimated that perhaps 100 to 200 new centers could ultimately open, with adoption occurring over time as hospitals make decisions, receive approvals and train staff.
Chief Financial Officer Doretta Mistras said the coverage changes create multi-year opportunities rather than a near-term surge followed by a decline. She said the company continues to expect durable TAVR growth in the mid- to high-single-digit range.
Moderate Aortic Stenosis Trial Nears Results Zovighian also discussed the company’s PROGRESS trial in moderate aortic stenosis, with results expected in approximately six weeks at the TCT meeting. He declined to speculate about potential outcomes or the market implications of different trial results.
He said Edwards launched the study based on its belief that treating aortic stenosis patients earlier, before further disease progression, could be beneficial. The study enrolled quickly, which he described as an encouraging sign of physician interest. However, he emphasized that the trial evaluates only the most severe moderate patients with at least one risk factor.
While acknowledging the potential size of the moderate patient population, Zovighian said it is difficult to precisely estimate the total addressable market before patients are broadly identified and treated. Mistras added that penetration in Edwards’ existing market remains in the low teens, leaving meaningful opportunity even without additional indications.
TMTT Portfolio Targets Further Growth For transcatheter mitral and tricuspid therapies, or TMTT, Zovighian said Edwards is focused on PASCAL for mitral regurgitation, PASCAL for tricuspid regurgitation, EVOQUE and SAPIEN M3. He said the business is on track for roughly $250 million in revenue and approximately 40% growth in 2026.
The company remains focused on its previously stated goal of more than $2 billion in TMTT revenue by 2030, though Zovighian said Edwards’ longer-term ambition is broader than that target. He cited millions of patients with mitral and tricuspid disease who lack treatment options.
Edwards expects a PASCAL tricuspid approval before year-end, which Zovighian said would add an incremental growth opportunity. EVOQUE is expanding through both new-center openings and increased utilization at existing centers, while SAPIEN M3 is in the early stages of its commercial launch following approval earlier this year, he said.
On tricuspid disease, Zovighian said the category remains early in its development because physicians had few options until recently. He pointed to the TRIC-I-HF study from German centers as evidence of progress in the field’s understanding, noting that the study showed a mortality benefit in addition to quality-of-life benefits.
Capital Allocation and Long-Term Focus Mistras said Edwards’ first capital-allocation priority is investment in internal capabilities, including its manufacturing network. The company also plans to evaluate external opportunities that fit its structural-heart strategy and allow Edwards to participate early in development. As a third priority, she said Edwards will continue to repurchase shares opportunistically, noting that it had bought back more than $500 million of stock year to date.
Zovighian said the company’s long-term target is to grow revenue by about 10%, supported by catalysts across its five therapy areas. He also said artificial intelligence could increasingly help hospitals improve disease awareness, imaging analysis, diagnostics and treatment decisions over the coming years.
About Edwards Lifesciences (NYSE:EW)Edwards Lifesciences Corporation NYSE: EW is a medical technology company focused on therapies for structural heart disease. Its products are designed to treat conditions affecting the heart valves and related cardiovascular structures, helping patients with diseases such as aortic stenosis, mitral regurgitation and tricuspid valve disorders.
The company's portfolio includes transcatheter aortic valve replacement systems, including its SAPIEN platform, as well as transcatheter mitral and tricuspid therapies and surgical heart valve products.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Edwards Lifesciences Right Now?Before you consider Edwards Lifesciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edwards Lifesciences wasn't on the list.
While Edwards Lifesciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Edwards Lifesciences Corporation (EW) Deutsche Bank 2026 Healthcare Summit September 16, 2026 10:00 AM EDT
Company Participants
Bernard Zovighian - CEO & Director
Theodora Mistras - Corporate VP & CFO
Conference Call Participants
Pito Chickering - Deutsche Bank AG, Research Division
Presentation
Pito Chickering
Deutsche Bank AG, Research Division
Good morning, everyone, and thanks for joining us today. Very, very pleased to host Edwards Lifesciences. So it's -- this should be a fun event. I guess, to start off with before we start asking questions, do you want to have any sort of opening statements or shall I just get right into this?
Bernard Zovighian
CEO & Director
So let's get into it. Good morning, everyone. It's great to be here. I'm glad you have interest in the company. We are pleased about all what we do. We take care of patients in the best way possible. And so we are very proud of the impact we are having.
Question-and-Answer Session
Pito Chickering
Deutsche Bank AG, Research Division
So Edwards is evolving from basically predominantly a TAVR story for the last decades into TMTT, which is increasing the part of the growth algorithm. I guess from a bigger picture, how should investors think about for the vision of the company and changing composition sort of in terms of TAVR, TMTT, PASCAL, also U.S., OUS for your long-term growth rate in the next sort of 3 to 5 years?
Bernard Zovighian
CEO & Director
Thanks, Pito. So let me start with a couple of comments. One is Doretta, our new CFO, has been with us 2 months now. She's an amazing partner. She gets the strategy of the company, and she's fully on board to enable this strategy and to accelerate this strategy. So let me talk about strategy very quickly. When a lot about this company is like we have strategic
On September 16, 2026, we delve into the DCF analysis for Edwards Lifesciences Corp EW, a company that has experienced a mixed price performance recently. The stock is currently trading at $85.74, reflecting a year-to-date increase of 0.6% and a one-year increase of 12.7%. However, the stock has seen a decline of 6.4% over the past month and 1.1% over the past week.
DCF Earnings-based intrinsic value of $53.13 vs current price of $85.74 (margin of safety: -61.4%) DCF Free Cash Flow (FCF)-based intrinsic value of $28.46 vs current price (second opinion) GF Score™ of 96/100, indicating a high level of reliability in the DCF inputs What Is EW Worth? DCF Earnings-Based Model The DCF earnings-based model for Edwards Lifesciences Corp considers a two-stage growth approach. In the first stage, we project earnings growth over the next ten years at a rate of 12.5%. The second stage accounts for a terminal growth rate of 4% for the following ten years. This model provides a comprehensive view of the company's potential earnings trajectory.
Parameter Value Current EPS (TTM, excl. non-recurring) $2.37 10-Year Growth Rate 12.5% 10-Year Treasury Rate 4.99% Discount Rate (ceil(Treasury) + 6%) 11% Terminal Growth Rate 4% The calculation summary for the DCF earnings-based model is as follows:
Stage Description Value Growth Stage (Years 1-10) EPS growing at 12.5%, discounted at 11% $30.27 Terminal Stage (Years 11-20) 4% terminal growth, discounted at 11% $22.86 Intrinsic Value Growth + Terminal $53.13 Comparing the current price of $85.74 with the intrinsic value of $53.13 indicates that the stock is significantly overvalued, with a margin of safety of -61.4%. It is important to note that GuruFocus utilizes EPS excluding non-recurring items, as research shows stock prices correlate more closely with earnings than free cash flow. For further calculations, you can visit the EW DCF Calculator.
What Does the Free Cash Flow DCF Say? The DCF model based on Free Cash Flow (FCF) yields an intrinsic value of $28.46. This figure further corroborates the earnings-based valuation, as both models indicate that the stock is significantly overvalued, with a margin of safety of -201.3%. The divergence between the earnings-based and FCF-based models highlights the uncertainty surrounding the valuation of Edwards Lifesciences Corp.
How Does GF Value™ Compare to the DCF Models? In addition to the DCF models, the GF Value™ for Edwards Lifesciences Corp stands at $95.48, suggesting that the stock is undervalued by 10.2%. GF Value™ is GuruFocus' proprietary measure that takes into account historical trading multiples, past business growth, and future performance estimates. The differing perspectives from the DCF models and GF Value™ indicate a lack of consensus on the stock's valuation, which investors should consider carefully. For more details, visit the GF Value™ page.
What Does EW's GF Score™ Tell Us? The GF Score™ evaluates a company's financial strength, profitability, growth potential, valuation, and momentum. Edwards Lifesciences Corp boasts a high GF Score™ of 96/100, suggesting strong fundamentals. However, the predictability rank is low at 1/5 stars, indicating that the DCF model may be less reliable for this stock due to its inherent volatility.
Metric Rating GF Score™ 96/100 Financial Strength 9/10 Profitability 9/10 Growth 9/10 Valuation 10/10 Momentum 10/10 For a deeper look at the company's metrics, visit the EW stock page.
Key Assumptions and Limitations It is essential to recognize that DCF models are highly sensitive to the assumptions made regarding growth rates and discount rates. Stocks with low predictability ratings, such as Edwards Lifesciences Corp, tend to produce less reliable DCF estimates. The terminal growth rate of 4% is a simplifying assumption that may not accurately reflect future market conditions.
What This Means for Investors In synthesizing the three valuation models—DCF earnings, DCF FCF, and GF Value™—it becomes clear that there is a significant disagreement regarding the valuation of Edwards Lifesciences Corp. While the DCF models indicate that the stock is overvalued, the GF Value™ suggests a more favorable outlook. Additionally, the Guru 13F activity shows that 15 gurus currently hold the stock, with 6 adding and 10 trimming their positions, while insiders have sold a total of $27.7 million over the past year. This mixed signal from guru ownership and insider activity adds another layer of complexity to the valuation. Investors should approach this stock with caution, considering the differing perspectives and the EW DCF Calculator for further insights.
Frequently Asked Questions What is EW's intrinsic value based on DCF?
Answer: earnings-based $53.13, FCF-based $28.46
Is EW overvalued or undervalued?
Answer: The consensus from the DCF models indicates that EW is overvalued, while GF Value™ suggests it is undervalued.
How reliable is the DCF model for EW?
Answer: The predictability rank is 1/5, indicating that the DCF model is less reliable for this stock.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Disclosures I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.
Index Dow Jones 0,98 % na 52573,3 b. S&P 500 0,86 % na 7656,98 b. Nasdaq Composite 0,96 % na 26333,0 b.
Páteční obchodování končí v zelené barvě. Z týdenního pohledu ale indexy klesají. Zkrácený týden přinesl indexu S&P 500 pokles o 0,8 %. Ceny ropy zmírňují poklesy po oznámení Saudské Arábie o nutnosti uzavření ropovodu spojujícího východ a západ země kvůli útokům. Futures na WTI setrvávají nad hranicí USD 100.
Index S&P 500 0,86 % na 7656,98 b. Nejsilnější sektory S&P Změna Nejslabší sektory S&P Změna Průmysl +1,3 % Utility -0,3 % Komunikační služby +1,3 % Zdravotnictví -0,1 % Informační technologie +1,1 % Energie 0 % Nejsilnější akcie S&P Změna Nejslabší akcie S&P Změna Hewlet Packard E. +12,4 % Albermarle -3,8 % Dell Technologies +12 % Seagate Technologies -3,7 % NetApp +8,5 % Sandisk -3,5 % ON Semiconductor +8,5 % Western Digital -3 % HP +8,4 % Edwards Lifesciences -2,8 %
Marek Kameništiak
Fio banka, a.s.
Prohlášení
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today issued the following statement in response to the national coverage determination (NCD) for transcatheter aortic valve replacement (TAVR) released by the Centers for Medicare & Medicaid Services (CMS):“Edwards is pleased that this updated policy represents an important step toward improving and expanding patient access to TAVR while reinforcing the value of a multidisciplinary Heart Team. Aortic stenosis is a serious, pro.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Edwards Lifesciences Corporation (NYSE: EW) breached their fiduciary duties to shareholders.
If you currently own Edwards stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected].
Why Your Participation Matters:
Shareholder involvement can help improve a company's policies, practices, and oversight mechanisms to create a more transparent, accountable, and effectively managed organization, which can enhance shareholder value.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) will participate in the Deutsche Bank Healthcare Summit on Wednesday, Sept. 16, 2026.Bernard Zovighian, chief executive officer, is scheduled to present at 10:00 a.m. ET. Doretta Mistras, chief financial officer, will also participate in the conference. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/, with an archived version accessibl.
Bank of Nova Scotia bought a new position in Edwards Lifesciences Corporation (NYSE:EW – Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 60,417 shares of the medical research company’s stock, valued at approximately $5,465,000.
Several other hedge funds also recently made changes to their positions in EW. BlackRock Inc. bought a new position in Edwards Lifesciences in the 2nd quarter worth $5,318,092,000. Bank of New York Mellon Corp purchased a new stake in Edwards Lifesciences in the second quarter worth about $1,274,082,000. Norges Bank bought a new position in shares of Edwards Lifesciences in the fourth quarter worth about $803,686,000. Deutsche Bank AG bought a new position in shares of Edwards Lifesciences in the second quarter worth about $516,552,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Edwards Lifesciences by 278.3% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock valued at $434,318,000 after buying an additional 4,108,270 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.
Edwards Lifesciences Stock Up 0.5% Shares of EW opened at $90.92 on Wednesday. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $96.29. The company has a market cap of $52.35 billion, a PE ratio of 52.25, a P/E/G ratio of 2.37 and a beta of 0.85. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The business has a fifty day moving average of $89.35 and a 200 day moving average of $84.82.
Edwards Lifesciences (NYSE:EW – Get Free Report) last released its earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. The firm had revenue of $1.74 billion for the quarter, compared to analysts’ expectations of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The company’s quarterly revenue was up 13.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, sell-side analysts expect that Edwards Lifesciences Corporation will post 3 EPS for the current year. Insider Transactions at Edwards Lifesciences In other Edwards Lifesciences news, VP Daniel J. Lippis sold 619 shares of the company’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total transaction of $56,966.57. Following the completion of the sale, the vice president owned 40,034 shares in the company, valued at $3,684,329.02. This represents a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the company’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $86.08, for a total value of $48,893.44. Following the sale, the senior vice president owned 15,334 shares of the company’s stock, valued at $1,319,950.72. This trade represents a 3.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 2,425 shares of company stock valued at $219,199. 0.31% of the stock is owned by insiders.
Analyst Ratings Changes A number of research analysts recently weighed in on the stock. Piper Sandler restated an “overweight” rating and set a $101.00 target price (up from $100.00) on shares of Edwards Lifesciences in a research note on Friday, July 24th. Leerink Partners upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $87.00 to $101.00 in a research note on Friday, July 24th. Royal Bank Of Canada boosted their price objective on Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Evercore reaffirmed an “outperform” rating and issued a $100.00 price objective on shares of Edwards Lifesciences in a research note on Monday, July 6th. Finally, Citigroup increased their target price on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Seventeen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $100.27.
Read Our Latest Stock Report on Edwards Lifesciences
(Free Report)
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
See Also Five stocks we like better than Edwards Lifesciences Pathward’s Credit Scare Tests Its Comeback Story Wiring the AI Boom: Rumble’s $13.7B Pivot StoneX: Too Far Too Fast? DICK’s Sporting Goods Faces Pain Now for a Bigger Prize Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW – Free Report).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
On August 26, 2026, we delve into the DCF analysis for Edwards Lifesciences Corp EW, a company that has seen a price performance of +12.4% over the past year and +6.6% year-to-date. However, the valuation models present a stark contrast:
DCF Earnings-based intrinsic value of $53.13 vs current price of $90.87 (margin of safety: -71.0%) DCF FCF-based intrinsic value of $28.46, indicating a second opinion on valuation GF Score™ of 94/100 suggests a strong overall performance, but with a predictability rank of 1/5 stars, the reliability of the DCF inputs is questionable What Is EW Worth? DCF Earnings-Based Model The DCF earnings-based model for Edwards Lifesciences Corp utilizes a two-stage approach. In the first stage, we project earnings growth over the next 10 years at a rate of 12.5%. The second stage accounts for a terminal growth rate of 4% for the subsequent 10 years. Below are the key assumptions used in our analysis:
Parameter Value Current EPS (TTM, excl. non-recurring) $2.81 10-Year Growth Rate 12.5% 10-Year Treasury Rate 4.64% Discount Rate (ceil(Treasury) + 6%) 11% Terminal Growth Rate 4% The following table summarizes the calculations for the two-stage DCF model:
Stage Description Value Growth Stage (Years 1-10) EPS growing at 12.5%, discounted at 11% $30.27 Terminal Stage (Years 11-20) 4% terminal growth, discounted at 11% $22.86 Intrinsic Value Growth + Terminal $53.13 With the current price at $90.87, the intrinsic value of $53.13 indicates that the stock is significantly overvalued, with a margin of safety of -71.0%. It is important to note that GuruFocus employs EPS figures that exclude non-recurring items, as research indicates that stock prices are more closely correlated with earnings than with free cash flow. For further details, you can access the EW DCF Calculator.
What Does the Free Cash Flow DCF Say? The free cash flow (FCF) based intrinsic value for Edwards Lifesciences Corp is calculated at $28.46. This figure starkly contrasts with the earnings-based intrinsic value of $53.13, reinforcing the notion that the stock is significantly overvalued, with a margin of safety of -219.3%. The divergence between these two models raises questions about the reliability of the earnings DCF in this case.
How Does GF Value™ Compare to the DCF Models? In addition to the DCF models, we consider the GF Value™ of $94.99, which provides a third perspective on valuation. GF Value™ is a proprietary measure from GuruFocus that integrates historical trading multiples, past business growth, and future performance estimates. The GF Value™ suggests a slight undervaluation compared to the current market price, but when viewed alongside the DCF models, it becomes evident that there is a lack of consensus on the stock's valuation.
For more insights, visit the GF Value™ page.
What Does EW's GF Score™ Tell Us? The GF Score™ evaluates a company's financial strength, profitability, growth potential, and valuation metrics. Edwards Lifesciences Corp boasts a strong GF Score™ of 94/100, indicating solid performance across various metrics. However, its predictability rank is only 1/5 stars, suggesting that the DCF model's reliability is compromised due to low predictability. Below is a summary of the GF Score™ metrics:
Metric Rating GF Score™ 94/100 Financial Strength 9/10 Profitability 9/10 Growth 9/10 Valuation 9/10 Momentum 7/10 For more details, check out the EW stock page.
Key Assumptions and Limitations It is crucial to recognize that DCF models are highly sensitive to the assumptions made regarding growth rates and discount rates. Additionally, stocks with low predictability ratings, such as Edwards Lifesciences Corp, yield less reliable DCF estimates. The terminal growth rate of 4% is a simplifying assumption that may not accurately reflect future performance.
What This Means for Investors In synthesizing the three valuation models—DCF earnings, DCF FCF, and GF Value™—it is evident that there is a significant disagreement among them. The earnings DCF suggests a substantial overvaluation, while the GF Value™ indicates a slight undervaluation. Given the low predictability rank of 1/5 stars, the DCF models should be approached with caution. Furthermore, the Guru 13F activity shows that 15 gurus currently hold the stock, with 6 adding and 10 trimming their positions, while insiders have sold $24.5 million worth of shares over the past year. This mixed signal from guru ownership and insider activity adds another layer of complexity to the investment outlook. For a deeper dive into the valuation, visit the EW DCF Calculator.
Frequently Asked Questions What is EW's intrinsic value based on DCF?
Answer: earnings-based $53.13, FCF-based $28.46
Is EW overvalued or undervalued?
Answer: The consensus from DCF and GF Value™ indicates that EW is significantly overvalued.
How reliable is the DCF model for EW?
Answer: The predictability rank of 1/5 suggests that the DCF model is less reliable for this stock.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Disclosures I/We may personally own shares in some of the companies mentioned above. However, those positions are not material to either the company or to my/our portfolios.
Beacon Pointe Advisors LLC bought a new position in Edwards Lifesciences Corporation (NYSE:EW – Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 128,603 shares of the medical research company’s stock, valued at approximately $11,632,000.
A number of other large investors have also modified their holdings of the company. Pin Oak Investment Advisors Inc. purchased a new position in shares of Edwards Lifesciences in the second quarter worth about $26,000. 49 Wealth Management LLC purchased a new position in shares of Edwards Lifesciences during the 2nd quarter worth $359,000. Livforsakringsbolaget Skandia Omsesidigt acquired a new stake in shares of Edwards Lifesciences during the 2nd quarter worth about $419,000. Orion Capital Management LLC purchased a new stake in Edwards Lifesciences in the 2nd quarter valued at about $138,000. Finally, Glenview Trust Co purchased a new stake in Edwards Lifesciences in the 2nd quarter valued at about $11,026,000. Institutional investors and hedge funds own 79.46% of the company’s stock.
Edwards Lifesciences Stock Performance NYSE:EW opened at $90.19 on Friday. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $96.29. The company has a fifty day simple moving average of $89.54 and a two-hundred day simple moving average of $85.03. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The company has a market cap of $51.93 billion, a price-to-earnings ratio of 51.83, a price-to-earnings-growth ratio of 2.36 and a beta of 0.85.
Edwards Lifesciences (NYSE:EW – Get Free Report) last released its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The firm had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. During the same period last year, the business posted $0.67 earnings per share. Edwards Lifesciences’s revenue was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, equities analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year. Insider Buying and Selling In related news, VP Daniel J. Lippis sold 619 shares of the business’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total transaction of $56,966.57. Following the completion of the transaction, the vice president owned 40,034 shares in the company, valued at approximately $3,684,329.02. The trade was a 1.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Annette Bruls sold 2,644 shares of the stock in a transaction on Friday, August 28th. The shares were sold at an average price of $89.98, for a total value of $237,907.12. Following the completion of the transaction, the vice president directly owned 17,984 shares in the company, valued at $1,618,200.32. This trade represents a 12.82% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 4,501 shares of company stock valued at $408,213 in the last quarter. 0.31% of the stock is owned by insiders.
Analyst Ratings Changes Several brokerages have weighed in on EW. Citigroup increased their target price on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. Mizuho upped their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a report on Wednesday, July 15th. Wall Street Zen cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. Truist Financial lifted their target price on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a report on Thursday, July 16th. Finally, TD Cowen reissued a “buy” rating on shares of Edwards Lifesciences in a research report on Tuesday, July 21st. Seventeen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, Edwards Lifesciences currently has an average rating of “Moderate Buy” and an average target price of $100.27.
Check Out Our Latest Stock Report on EW
Edwards Lifesciences Profile (Free Report)
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
Featured Articles Five stocks we like better than Edwards Lifesciences 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude? Okta Stock Surges 29%—Is $200 the Next Stop? Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW – Free Report).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
EP Wealth Advisors LLC bought a new position in Edwards Lifesciences Corporation (NYSE:EW – Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 37,702 shares of the medical research company’s stock, valued at approximately $3,410,000.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. BlackRock Inc. bought a new stake in Edwards Lifesciences in the 2nd quarter valued at $5,318,092,000. State Street Corp increased its holdings in shares of Edwards Lifesciences by 1.5% during the 4th quarter. State Street Corp now owns 25,991,524 shares of the medical research company’s stock worth $2,215,777,000 after purchasing an additional 371,892 shares during the period. Wellington Management Group LLP raised its position in shares of Edwards Lifesciences by 4.8% during the fourth quarter. Wellington Management Group LLP now owns 21,793,949 shares of the medical research company’s stock valued at $1,857,934,000 after buying an additional 989,533 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Edwards Lifesciences during the second quarter valued at about $1,274,082,000. Finally, Norges Bank bought a new stake in shares of Edwards Lifesciences in the fourth quarter valued at about $803,686,000. Institutional investors and hedge funds own 79.46% of the company’s stock.
Edwards Lifesciences Stock Up 0.1% Shares of NYSE:EW opened at $89.89 on Friday. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $96.29. The company’s 50-day moving average price is $89.21 and its two-hundred day moving average price is $84.67. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The firm has a market cap of $51.76 billion, a P/E ratio of 51.66, a P/E/G ratio of 2.26 and a beta of 0.85.
Edwards Lifesciences (NYSE:EW – Get Free Report) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. The firm had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The business’s quarterly revenue was up 13.6% compared to the same quarter last year. During the same period last year, the company earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, research analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year. Wall Street Analysts Forecast Growth EW has been the topic of several recent research reports. BTIG Research lifted their price objective on Edwards Lifesciences from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Citigroup upped their target price on Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday, July 8th. Truist Financial raised their target price on Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “hold” rating in a research report on Thursday, July 16th. TD Cowen reiterated a “buy” rating on shares of Edwards Lifesciences in a research note on Tuesday, July 21st. Finally, Evercore reissued an “outperform” rating and issued a $100.00 price target on shares of Edwards Lifesciences in a report on Monday, July 6th. Seventeen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $100.27.
View Our Latest Stock Analysis on Edwards Lifesciences
Insider Buying and Selling at Edwards Lifesciences In related news, VP Donald E. Bobo, Jr. sold 23,145 shares of the stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the sale, the vice president directly owned 98,611 shares in the company, valued at $8,521,962.62. This trade represents a 19.01% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Andrew M. Dahl sold 568 shares of the stock in a transaction on Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the sale, the senior vice president owned 15,334 shares in the company, valued at approximately $1,319,950.72. This trade represents a 3.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 25,570 shares of company stock valued at $2,219,390. 0.31% of the stock is currently owned by company insiders.
(Free Report)
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
Featured Articles Five stocks we like better than Edwards Lifesciences 2 Biotech Stocks Shaping Up for Major Breakouts 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit? Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW – Free Report).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
B. Metzler seel. Sohn & Co. AG acquired a new position in Edwards Lifesciences Corporation (NYSE:EW – Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 41,753 shares of the medical research company’s stock, valued at approximately $3,777,000.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in EW. TrinityBridge Ltd bought a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at approximately $27,000. MV Capital Management Inc. bought a new position in Edwards Lifesciences during the 4th quarter valued at about $26,000. Hanson & Doremus Investment Management acquired a new position in Edwards Lifesciences in the first quarter valued at about $25,000. Kemnay Advisory Services Inc. acquired a new position in Edwards Lifesciences in the fourth quarter valued at about $27,000. Finally, JPL Wealth Management LLC bought a new stake in Edwards Lifesciences during the third quarter worth about $25,000. Institutional investors and hedge funds own 79.46% of the company’s stock.
Analyst Ratings Changes A number of equities research analysts recently commented on EW shares. Citigroup increased their price target on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Leerink Partners upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and raised their price target for the company from $87.00 to $101.00 in a report on Friday, July 24th. Barclays reiterated an “overweight” rating and issued a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. Mizuho boosted their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a report on Wednesday, July 15th. Finally, TD Cowen restated a “buy” rating on shares of Edwards Lifesciences in a report on Tuesday, July 21st. Seventeen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $100.27.
Read Our Latest Research Report on Edwards Lifesciences Edwards Lifesciences Price Performance Shares of Edwards Lifesciences stock opened at $89.89 on Friday. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $51.76 billion, a price-to-earnings ratio of 51.66, a price-to-earnings-growth ratio of 2.26 and a beta of 0.85. The company has a 50-day simple moving average of $89.21 and a two-hundred day simple moving average of $84.67. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $96.29.
Edwards Lifesciences (NYSE:EW – Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. The firm had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The company’s revenue was up 13.6% on a year-over-year basis. During the same quarter last year, the company earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current year.
Insider Activity In other Edwards Lifesciences news, VP Daniel J. Lippis sold 619 shares of the company’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total transaction of $56,966.57. Following the completion of the sale, the vice president directly owned 40,034 shares in the company, valued at $3,684,329.02. This represents a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the company’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $86.08, for a total value of $48,893.44. Following the sale, the senior vice president owned 15,334 shares of the company’s stock, valued at approximately $1,319,950.72. This represents a 3.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 25,570 shares of company stock worth $2,219,390. 0.31% of the stock is currently owned by corporate insiders.
(Free Report)
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
Featured Stories Five stocks we like better than Edwards Lifesciences Blueprint for a Boom: SEC Clears the Crypto Runway Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss Advance Auto Parts Plunged, But Its Turnaround Is Still Working Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
Allworth Financial LP bought a new position in Edwards Lifesciences Corporation (NYSE:EW – Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 16,600 shares of the medical research company’s stock, valued at approximately $1,502,000.
A number of other hedge funds have also modified their holdings of EW. Hanson & Doremus Investment Management purchased a new position in shares of Edwards Lifesciences in the first quarter worth approximately $25,000. JPL Wealth Management LLC acquired a new position in Edwards Lifesciences in the 3rd quarter worth about $25,000. MV Capital Management Inc. bought a new stake in shares of Edwards Lifesciences during the 4th quarter worth about $26,000. RMG Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences in the first quarter worth $26,000. Finally, TrinityBridge Ltd bought a new position in Edwards Lifesciences in the 2nd quarter worth approximately $27,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling In other news, VP Donald E. Bobo, Jr. sold 23,145 shares of Edwards Lifesciences stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the completion of the sale, the vice president owned 98,611 shares in the company, valued at $8,521,962.62. The trade was a 19.01% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Daniel J. Lippis sold 619 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total transaction of $56,966.57. Following the transaction, the vice president directly owned 40,034 shares in the company, valued at $3,684,329.02. This trade represents a 1.52% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 25,570 shares of company stock valued at $2,219,390 in the last three months. Insiders own 0.31% of the company’s stock.
Edwards Lifesciences Price Performance Shares of Edwards Lifesciences stock opened at $89.89 on Friday. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $51.76 billion, a price-to-earnings ratio of 51.66, a price-to-earnings-growth ratio of 2.26 and a beta of 0.85. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $96.29. The company has a 50-day simple moving average of $89.21 and a two-hundred day simple moving average of $84.67. Edwards Lifesciences (NYSE:EW – Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. The firm had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The company’s revenue was up 13.6% on a year-over-year basis. During the same quarter last year, the company earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current year.
Analyst Upgrades and Downgrades A number of research analysts have commented on EW shares. Piper Sandler restated an “overweight” rating and set a $101.00 price target (up from $100.00) on shares of Edwards Lifesciences in a research note on Friday, July 24th. Leerink Partners raised shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $87.00 to $101.00 in a research note on Friday, July 24th. Mizuho lifted their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 15th. TD Cowen reiterated a “buy” rating on shares of Edwards Lifesciences in a report on Tuesday, July 21st. Finally, Royal Bank Of Canada upped their target price on Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Seventeen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $100.27.
Read Our Latest Research Report on Edwards Lifesciences
(Free Report)
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
See Also Five stocks we like better than Edwards Lifesciences Blueprint for a Boom: SEC Clears the Crypto Runway Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss Advance Auto Parts Plunged, But Its Turnaround Is Still Working Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
Key Takeaways Edwards Lifesciences' TMTT sales rose 44.8%, while TAVR sales increased 10.5% at constant currency. EW's TAVR growth is supported by SAPIEN investments, clinical evidence and broader treatment opportunities. Edwards Lifesciences expects FX to cut second-half sales by about $35 million if current rates persist. Edwards Lifesciences’ (EW - Free Report) Transcatheter Mitral and Tricuspid Therapies (“TMTT”) business has seen consistent growth over the past few quarters, which is highly encouraging. The company’s TAVR platform represents another significant growth opportunity, supported by patient activation and advanced new technologies. However, ongoing currency swings and intense competition could weigh on Edwards’ financial results.
Over the past year, this Zacks Rank #3 (Hold) stock has gained 16.9% against the 6.5% decline of the industry. The S&P 500 composite rose 22.3% at the same time.
The renowned global medical device company has a market capitalization of $49.51 billion. EW’s earnings yield of 3.3% favorably compares with the industry’s negative 1.6% yield. In the trailing four quarters, Edwards delivered an average earnings surprise of 4.5%.
Let’s delve deeper.
Upsides for EW StockTAVR Holds Potential: Edwards’ TAVR franchise continues to benefit from the clinical and technology investments built around the SAPIEN platform. Second-quarter 2026 TAVR sales were about $1.3 billion and increased 10.5% on a constant-currency basis. The evidence base continues to support broader and earlier treatment. A seven-year PARTNER 3 subanalysis reinforced SAPIEN valve performance and durability, while a five-year EARLY TAVR analysis added evidence supporting intervention earlier in the aortic-stenosis disease pathway.
Updated European guidelines are also shaping clinical discussion around proactive treatment, and Japan approved the asymptomatic indication in second-quarter 2026. The next catalyst is the PROGRESS trial, which will evaluate whether certain moderate aortic-stenosis patients may benefit from earlier TAVR treatment.
TMTT Portfolio Holds Potential: Edwards’ TMTT portfolio remains a major source of growth as it scales repair and replacement therapies across mitral and tricuspid disease. Second-quarter 2026 TMTT sales were $195.9 million, up 44.8% on a constant-currency basis, with global mitral and tricuspid procedure growth remaining in the double digits. PASCAL, EVOQUE and SAPIEN M3 all contributed ahead of management’s expectations.
During second-quarter 2026, Edwards received CE Mark for SAPIEN M3 RESILIA and broadened the European indication for SAPIEN M3 and SAPIEN M3 RESILIA to patients with mitral annular calcification. ENCIRCLE registry data also showed low 30-day mortality, near elimination of regurgitation and quality-of-life improvement in this population.
Image Source: Zacks Investment Research
What Ails EW Stock?Foreign Exchange Remains a Margin Risk: Currency movements remain an important earnings variable because Edwards generates substantial sales and expenses outside the United States. Foreign exchange increased second-quarter 2026 reported sales by about $15 million, but reduced adjusted gross margin by roughly 70 basis points compared with the prior year. Management expects foreign exchange to reduce second-half sales by about $35 million if rates remain at current levels and now sees 2026 gross margin near the lower end of its 78% to 79% range.
Competitive Landscape Remains Intense: Structural heart remains a highly competitive medical-technology market, requiring continued investment in evidence, product development and physician adoption. Edwards reported modest year-over-year competitive-position gains in U.S. and European TAVR during second-quarter 2026, but part of growth still reflected a competitor’s 2025 market exit, with management indicating the European benefit was likely ending after the quarter. The company, therefore, must sustain SAPIEN differentiation as that comparison rolls off. Edwards is investing in next-generation SAPIEN and PASCAL technologies, yet failure to maintain technological or evidence advantages could weaken share and raise commercial spending over time.
EW Stock Estimate TrendThe Zacks Consensus Estimate for Edwards’ 2026 earnings per share (EPS) has remained constant at $3.00 in the past 30 days.
The consensus estimate for its 2026 revenues is pegged at $6.76 billion, indicating an 11.4% improvement from the year-ago reported number.
Key PicksSome better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and Teleflex (TFX - Free Report) .
Globus Medical has an earnings yield of 5.8% in contrast to the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED’s shares have rallied 42.3% against the industry’s 6.3% fall over the past year.
GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Veracyte, sporting a Zacks Rank #1, has an earnings yield of 4.6% compared to the industry’s negative 1.7% yield. Shares of the company have risen 38% against the industry’s 6.3% decline. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%.
Teleflex, carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 20.7% compared with the industry’s 12.8% rise. Its earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.2%. TFX’s shares have rallied 5% against the industry’s 6.2% decline over the past year.
BlackRock Inc. bought a new position in Edwards Lifesciences Corporation (NYSE:EW – Free Report) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm bought 58,789,433 shares of the medical research company’s stock, valued at approximately $5,318,092,000. BlackRock Inc. owned approximately 10.21% of Edwards Lifesciences at the end of the most recent reporting period.
Other large investors have also made changes to their positions in the company. Hanson & Doremus Investment Management purchased a new stake in Edwards Lifesciences in the 1st quarter valued at about $25,000. JPL Wealth Management LLC acquired a new position in Edwards Lifesciences in the 3rd quarter valued at about $25,000. MV Capital Management Inc. purchased a new stake in Edwards Lifesciences during the fourth quarter worth about $26,000. RMG Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences during the first quarter worth about $26,000. Finally, Kemnay Advisory Services Inc. acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth about $27,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.
Edwards Lifesciences Stock Up 0.4% Shares of NYSE EW opened at $91.13 on Wednesday. The stock has a market capitalization of $52.47 billion, a price-to-earnings ratio of 52.37, a price-to-earnings-growth ratio of 2.30 and a beta of 0.85. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $96.29. The firm has a 50-day moving average price of $88.90 and a 200 day moving average price of $84.49. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06.
Edwards Lifesciences (NYSE:EW – Get Free Report) last released its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. The company had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The firm’s quarterly revenue was up 13.6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities research analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year. Insider Buying and Selling In other Edwards Lifesciences news, VP Daniel J. Lippis sold 619 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total transaction of $56,966.57. Following the completion of the sale, the vice president directly owned 40,034 shares in the company, valued at $3,684,329.02. The trade was a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the completion of the sale, the vice president owned 98,611 shares of the company’s stock, valued at approximately $8,521,962.62. This trade represents a 19.01% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 25,570 shares of company stock valued at $2,219,390. 0.31% of the stock is currently owned by corporate insiders.
Wall Street Analysts Forecast Growth A number of research analysts recently issued reports on the company. Citigroup lifted their target price on Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Evercore restated an “outperform” rating and set a $100.00 target price on shares of Edwards Lifesciences in a research note on Monday, July 6th. UBS Group assumed coverage on shares of Edwards Lifesciences in a report on Tuesday, July 28th. They issued a “buy” rating and a $110.00 target price on the stock. TD Cowen reiterated a “buy” rating on shares of Edwards Lifesciences in a research note on Tuesday, July 21st. Finally, Canaccord Genuity Group set a $85.00 price target on shares of Edwards Lifesciences and gave the stock a “hold” rating in a report on Friday, April 24th. Seventeen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $100.27.
Read Our Latest Research Report on EW
Edwards Lifesciences Company Profile (Free Report)
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
Read More Five stocks we like better than Edwards Lifesciences The AI Boom Is Turning This Cable Maker Into a Stock to Watch A Star Investor Just Trimmed Amazon—Here’s What It means Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look Home Depot Analysts See a Path to $375 and Beyond
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
Baxter Bros Inc. purchased a new stake in shares of Edwards Lifesciences Corporation (NYSE: EW) during the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 39,184 shares of the medical research company's stock, valued at approximately $3,545,000. A number of other large investors have
Bank Hapoalim BM purchased a new stake in Edwards Lifesciences Corporation (NYSE:EW – Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 19,640 shares of the medical research company’s stock, valued at approximately $1,777,000.
A number of other large investors have also recently modified their holdings of EW. Brighton Jones LLC bought a new position in shares of Edwards Lifesciences in the fourth quarter worth approximately $266,000. NewEdge Advisors LLC raised its stake in Edwards Lifesciences by 8.1% in the second quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company’s stock valued at $2,787,000 after purchasing an additional 2,665 shares in the last quarter. Sei Investments Co. lifted its position in Edwards Lifesciences by 16.7% during the second quarter. Sei Investments Co. now owns 412,808 shares of the medical research company’s stock valued at $32,285,000 after purchasing an additional 58,988 shares during the last quarter. Squarepoint Ops LLC lifted its position in Edwards Lifesciences by 277.7% during the second quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company’s stock valued at $5,417,000 after purchasing an additional 50,924 shares during the last quarter. Finally, Treasurer of the State of North Carolina grew its stake in Edwards Lifesciences by 0.4% in the 2nd quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company’s stock worth $21,028,000 after buying an additional 1,065 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.
Analyst Upgrades and Downgrades A number of equities analysts have recently commented on EW shares. TD Cowen reissued a “buy” rating on shares of Edwards Lifesciences in a report on Tuesday, July 21st. Barclays reaffirmed an “overweight” rating and set a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a report on Monday, April 27th. Mizuho upped their target price on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th. Robert W. Baird increased their target price on Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a research note on Friday, April 24th. Finally, UBS Group started coverage on Edwards Lifesciences in a research report on Tuesday, July 28th. They set a “buy” rating and a $110.00 price target on the stock. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $100.27.
View Our Latest Stock Analysis on EW
Insider Activity In other news, VP Donald E. Bobo, Jr. sold 23,145 shares of the business’s stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total value of $2,000,190.90. Following the completion of the sale, the vice president owned 98,611 shares of the company’s stock, valued at approximately $8,521,962.62. The trade was a 19.01% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Andrew M. Dahl sold 568 shares of the stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the sale, the senior vice president owned 15,334 shares of the company’s stock, valued at $1,319,950.72. This represents a 3.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 26,190 shares of company stock valued at $2,269,697. 0.31% of the stock is currently owned by insiders.
Edwards Lifesciences Trading Down 1.1% Shares of EW opened at $91.51 on Friday. Edwards Lifesciences Corporation has a fifty-two week low of $72.30 and a fifty-two week high of $96.29. The firm has a market cap of $52.69 billion, a price-to-earnings ratio of 52.59, a PEG ratio of 2.30 and a beta of 0.85. The firm has a 50 day moving average price of $88.73 and a 200-day moving average price of $84.37. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52.
Edwards Lifesciences (NYSE:EW – Get Free Report) last released its earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.74 by $0.04. The company had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The firm’s quarterly revenue was up 13.6% compared to the same quarter last year. During the same quarter last year, the firm earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, equities research analysts forecast that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.
Edwards Lifesciences Profile (Free Report)
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
Further Reading Five stocks we like better than Edwards Lifesciences Is Best Buy the AI Winner Hiding in the Electronics Aisle? Applied Materials Beat Everything but Wall Street’s Expectations for Margins Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW – Free Report).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEBallentine Partners LLC Buys 22,470 Shares of Vanguard Information Technology ETF $VGT
NEXT HEADLINE »Barnes Pettey Financial Advisors LLC Buys 51,353 Shares of Vanguard Growth ETF $VUG
Key Takeaways EW's Q2 revenues rose 13.6%, while adjusted earnings increased 16.4% to 78 cents per share. EW raised 2026 TAVR growth guidance to 8-9% and companywide sales growth guidance to 10-11%. EW trades at 28.78 times forward earnings, above its sub-industry, sector and S&P 500 benchmarks. Edwards Lifesciences Corporation (EW - Free Report) is entering the second half of 2026 with faster structural heart growth and better operating leverage. Second-quarter revenues rose 13.6% to $1.74 billion, while adjusted earnings increased 16.4% to 78 cents per share.
The question is whether that momentum warrants a premium valuation. TAVR and TMTT are expanding, but foreign exchange, litigation, reimbursement dependence and competition raise the hurdle for further upside.
EW’s Growth Profile Is Getting StrongerSecond-quarter adjusted operating income rose 20.8% to $522.7 million, and adjusted operating margin expanded 180 basis points to 30%. Revenue growth outpaced operating-expense growth enough to produce meaningful earnings leverage.
TAVR sales totaled $1.26 billion, up 10.5% at constant currency. Management raised 2026 TAVR constant-currency growth guidance to 8-9% from 7-9% and lifted companywide constant-currency sales growth guidance to 10-11% from 9-11%. The Zacks Consensus Estimate projects 2026 company revenue growth of 11.1%.
Edwards’ TMTT Portfolio Expands the OpportunityTranscatheter Mitral and Tricuspid Therapies sales reached $195.9 million in the second quarter, up 44.8% at constant currency. PASCAL, EVOQUE and SAPIEN M3 all contributed ahead of management’s expectations as adoption broadened across mitral and tricuspid procedures.
Management raised 2026 TMTT sales guidance to $760-$780 million from $740-$780 million and continues to target $2 billion in TMTT revenues by 2030. That faster-growing platform gives Edwards a second major avenue alongside its much larger TAVR franchise.
Based on short-term price targets offered by 27 analysts, the average price target for Edwards Lifesciences comes to $101.78. The average price target represents an increase of 9.38% from the last closing price.
Image Source: Zacks Investment Research
EW’s Premium Valuation Raises the BarEW trades at a forward 12-month price-to-earnings ratio of 28.78, compared with 27.25 for the Zacks sub-industry, 21.15 for the Zacks sector and 20.66 for the S&P 500. Its five-year median is 30, so the stock is not far from its own longer-term norm despite trading above broader benchmarks.
The premium matters because large medical-device peers are still investing aggressively. Abbott Laboratories (ABT - Free Report) reported 9% second-quarter 2026 Medical Devices sales growth, while Boston Scientific Corporation (BSX - Free Report) posted 8.3% growth in cardiovascular sales. Those results reinforce the competitive intensity surrounding high-growth cardiovascular markets.
Edwards Faces Margin and Execution RisksAdjusted gross margin was 77.6% in the second quarter, unchanged year over year, as lower manufacturing expenses offset a roughly 70-basis-point foreign-exchange headwind. Management expects 2026 gross margin near the lower end of its 78%-79% range.
Litigation, tariffs and reimbursement add execution uncertainty. Edwards also expects its 2026 tax rate at the high end of the prior 16-19% range and faces intense competition as a prior competitor-exit benefit rolls off in Europe. Sustaining differentiation in SAPIEN and newer structural heart platforms remains important.
In the past year, EW shares rose 18.4% outperforming the industry’s 3.2% decline.
Image Source: Zacks Investment Research
EW’s Growth Score Supports a Patient ApproachThe investment case remains balanced. Edwards has expanding structural heart opportunities, improving operating leverage and ample liquidity, but its valuation already reflects a meaningful growth premium and leaves less room for execution setbacks for investors considering new positions.
EW currently carries a Zacks Rank #3 (Hold). Its Growth Score of A supports the strength of its growth characteristics, but a Value Score of D and Momentum Score of F temper the setup. The VGM Score of C points to a mixed profile across value, growth and momentum. Because Zacks Style Scores are designed to complement the Zacks Rank, this combination favors patience rather than treating growth alone as a sufficient buy signal.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Key Takeaways Edwards gained 14% in three months as TAVR and TMTT growth strengthened its operating case. TMTT sales rose 44.8% at constant currency, prompting Edwards to raise its 2026 sales outlook. FX, litigation, reimbursement and competition remain risks as Edwards trades at 28.8X forward EPS. Edwards Lifesciences Corporation (EW - Free Report) shares have gained 14% in the past three months as growth across its structural-heart franchises has strengthened the operating case. Second-quarter results showed double-digit expansion in transcatheter aortic valve replacement and faster growth in transcatheter mitral and tricuspid therapies.
The rally leaves investors balancing broader growth and raised 2026 expectations against a valuation that already reflects meaningful execution.
EW’s 3-Month Gain Meets a Premium ValuationEW trades at 28.8X forward 12-month EPS, above 27.3X for the Zacks sub-industry and 20.7X for the S&P 500. The stock has also outpaced the S&P 500’s 4.5% gain over the past three months, although it trails the sub-industry’s 18.9% advance.
Image Source: Zacks Investment Research
The current multiple is close to Edwards’ five-year median of 30.0X. That positioning suggests the market is already assigning substantial value to continued growth, leaving less room for execution setbacks after the recent share-price increase.
Edwards’ Growth Engines Remain Broad-BasedSecond-quarter 2026 TAVR sales reached $1.26 billion, rising 10.5% at constant currency. TMTT sales increased 44.8% at constant currency to $195.9 million, while Surgical sales advanced 5% at constant currency to $284 million.
The mix matters because Edwards is not relying on a single franchise. TAVR remains the largest platform, Surgical continues to benefit from RESILIA-based technologies and TMTT is adding a faster-growth layer. Medtronic plc (MDT - Free Report) remains a relevant structural-heart competitor, with its Evolut TAVR platform supported by ongoing clinical evidence.
EW’s TMTT Momentum Adds a Faster-Growth LayerPASCAL, EVOQUE and SAPIEN M3 all contributed ahead of management’s expectations in the second quarter. PASCAL adoption increased, EVOQUE expanded through new and existing centers, and SAPIEN M3 broadened Edwards’ mitral replacement offering.
Management raised its 2026 TMTT sales outlook to $760-$780 million from $740-$780 million and continues to target $2 billion in TMTT revenues by 2030. That target highlights the franchise’s role in Edwards’ longer-term growth plan as access broadens and treatment centers gain experience.
Edwards Faces FX, Litigation and Coverage RisksForeign exchange reduced adjusted gross margin by about 70 basis points in the second quarter, even as it added roughly $15 million to reported sales. Management expects foreign exchange to reduce second-half sales by about $35 million if rates remain at current levels and sees 2026 gross margin near the lower end of its 78-79% range.
Per the Zacks Consensus Estimates, the company’s 2026 earnings and revenues are pegged at $3.00 and $6.76 billion, respectively.
Image Source: Zacks Investment Research
Litigation also remains unresolved, while reimbursement and trade policy could affect demand, access and costs. Management expects a final U.S. TAVR coverage decision in September 2026. Boston Scientific Corporation (BSX - Free Report) is also pursuing a potential entry into balloon-expandable TAVR through its 2026 investment in MiRus, underscoring the competitive intensity surrounding structural-heart therapies.
EW’s Mixed Signals Temper the Rally CaseEdwards’ growth profile remains favorable, but the recent advance and premium valuation make further gains more dependent on execution. Continued TAVR expansion, TMTT scaling and supportive coverage developments could help the operating case, while currency, legal and competitive risks may pressure returns.
EW currently carries a Zacks Rank #3 (Hold) and a VGM Score of C. Its Growth Score of A supports the company’s growth characteristics, while the Value Score of D and Momentum Score of F are less favorable. Together, those signals argue for selectivity after the three-month rally rather than an aggressive stance based on price performance alone.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
On August 05, 2026, we delve into the DCF analysis for Edwards Lifesciences Corp (EW), a company that has shown mixed price performance recently. The stock has
Glenmede Trust Co. NA trimmed its stake in shares of Edwards Lifesciences Corporation (NYSE:EW – Free Report) by 4.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 167,483 shares of the medical research company’s stock after selling 6,923 shares during the period. Glenmede Trust Co. NA’s holdings in Edwards Lifesciences were worth $13,412,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Norges Bank purchased a new stake in shares of Edwards Lifesciences in the fourth quarter valued at $803,686,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Edwards Lifesciences by 278.3% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock valued at $434,318,000 after buying an additional 4,108,270 shares in the last quarter. Viking Global Investors LP purchased a new position in shares of Edwards Lifesciences during the third quarter valued at $238,688,000. Marshall Wace LLP raised its position in Edwards Lifesciences by 66.1% during the fourth quarter. Marshall Wace LLP now owns 5,925,627 shares of the medical research company’s stock valued at $505,160,000 after buying an additional 2,359,128 shares during the period. Finally, Bank of America Corp DE lifted its stake in Edwards Lifesciences by 132.4% in the 1st quarter. Bank of America Corp DE now owns 3,883,419 shares of the medical research company’s stock worth $310,984,000 after acquiring an additional 2,212,208 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.
Insider Buying and Selling In related news, VP Donald E. Bobo, Jr. sold 23,145 shares of Edwards Lifesciences stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the transaction, the vice president owned 98,611 shares in the company, valued at $8,521,962.62. This trade represents a 19.01% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Andrew M. Dahl sold 568 shares of the business’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the transaction, the senior vice president directly owned 15,334 shares of the company’s stock, valued at approximately $1,319,950.72. This represents a 3.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 43,539 shares of company stock valued at $3,685,364. Company insiders own 0.31% of the company’s stock.
Edwards Lifesciences Stock Up 0.1% EW opened at $86.17 on Monday. The business has a 50 day moving average price of $87.91 and a 200 day moving average price of $83.90. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $96.29. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42. The firm has a market cap of $49.62 billion, a P/E ratio of 49.52, a price-to-earnings-growth ratio of 2.16 and a beta of 0.85.
Edwards Lifesciences (NYSE:EW – Get Free Report) last announced its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.85% and a net margin of 15.43%.The firm had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.70 billion. During the same quarter in the prior year, the business earned $0.67 earnings per share. The company’s revenue was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Research analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current year.
Analysts Set New Price Targets Several research firms have weighed in on EW. Mizuho lifted their target price on Edwards Lifesciences from $100.00 to $105.00 and gave the company an “outperform” rating in a research note on Wednesday, July 15th. Canaccord Genuity Group set a $85.00 target price on Edwards Lifesciences and gave the stock a “hold” rating in a research report on Friday, April 24th. Citigroup raised their price target on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. Piper Sandler reissued an “overweight” rating and issued a $101.00 price target (up from $100.00) on shares of Edwards Lifesciences in a research note on Friday, July 24th. Finally, Barclays restated an “overweight” rating and issued a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a report on Monday, April 27th. Seventeen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Edwards Lifesciences currently has an average rating of “Moderate Buy” and a consensus target price of $100.27.
View Our Latest Report on Edwards Lifesciences
Edwards Lifesciences Profile (Free Report)
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
See Also Five stocks we like better than Edwards Lifesciences 3 Fixed-Income ETFs Show Why Yield Is Only Part of the Income Story AbbVie Quietly Solved Its Biggest Problem—Now What? Rio Tinto’s Results Make the Case for Looking Beyond Tech in the AI Trade Strategy’s Structural Strength: Hidden in a $8 Billion Illusion
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEGlenmede Trust Co. NA Boosts Stock Holdings in Meta Platforms, Inc. $META
NEXT HEADLINE »Edgestream Partners L.P. Trims Stock Holdings in SPDR Blackstone Senior Loan ETF $SRLN
Investors in Edwards Lifesciences, Inc. (EW - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the August 21, 2026 $45.00 Call had some of the highest implied volatility of all equity options today.
What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.
What do the Analysts Think?Clearly, options traders are pricing in a big move for Edwards Lifesciences share, but what is the fundamental picture for the company? Currently, Edwards Lifesciences is a Zacks Rank #3 (Hold) in the Internet - Software Industry that ranks in the Top 38% of our Zacks Industry Rank. Over the last 60 days, seven analysts have increased their estimates for the current quarter, while none have revised their estimates downward. The net effect has taken our Zacks Consensus Estimate for the current quarter to move from $3.03 per share to $3.12 per share in the same time period.
Given the way analysts feel about Edwards Lifesciences right now, this huge implied volatility could mean there’s a trade developing. Often times, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.
The company reported adjusted earnings of 78 cents per share for the second quarter, beating the analyst consensus estimate of 74 cents. Revenue increased to $1.741 billion from a year earlier, exceeding the $1.70 billion consensus estimate.
Total sales rose 13.6% year over year, or 12.5% on a constant-currency basis.
TAVR, TMTT Businesses Fuel GrowthTranscatheter Aortic Valve Replacement (TAVR) sales increased 11.3% year over year, or 10.5% in constant currency, to $1.3 billion.
The company said procedural growth benefited from sustained clinical momentum and growing evidence supporting earlier treatment of severe aortic stenosis. Growth was similar in the U.S. and international markets and also benefited from a competitor’s market exit in 2025.
Transcatheter Mitral and Tricuspid Therapies (TMTT) revenue climbed to $195.9 million, supported by continued demand for the company’s repair and replacement therapies. Edwards said mitral and tricuspid procedure growth remained in the double digits globally.
Surgical segment sales rose 6.5% from a year earlier to $284 million, or 5% in constant currency. The increase was driven by continued adoption of the company’s RESILIA tissue technologies.
Company Raises Revenue OutlookEdwards reaffirmed its fiscal 2026 adjusted earnings guidance of $2.95 to $3.05 per share. That range brackets the Wall Street consensus estimate of $3.01.
The company also raised the low end of its full-year revenue guidance. It now expects revenue of $6.60 billion to $6.90 billion, up from its previous forecast of $6.50 billion to $6.90 billion. The updated range brackets the Wall Street consensus estimate of $6.745 billion.
Edwards also reaffirmed its expectation for 2026 TAVR sales of $4.75 billion to $5.0 billion.
Analyst Sees More Upside AheadWilliam Blair analyst Brandon Vazquez said Friday that the results reinforced the firm’s bullish outlook on Edwards.
“Overall, the second quarter reaffirmed our bullish thesis on Edwards shares, offering one of the better setups for medtech growth,” Vazquez wrote.
The analyst maintained an Outperform rating, saying the stock, trading at about 26 times projected 2027 earnings, could see further upside as earnings grow and additional catalysts emerge in the second half of 2026 and into 2027.
EW Stock Price Activity: Edwards Lifesciences shares were up 3.32% at $86.60 at the time of publication on Friday, according to Benzinga Pro data.
Market News and Data brought to you by Benzinga APIs
Key Takeaways Edwards Lifesciences topped Q2 earnings and revenue estimates, with shares rising nearly 3% after hours.EW raised 2026 sales growth guidance as TAVR demand and TMTT adoption remained strong.Edwards Lifesciences reaffirmed 2026 earnings guidance and expects Q3 revenues of $1.63B-$1.71B. Edwards Lifesciences Corporation (EW - Free Report) reported second-quarter 2026 adjusted earnings of 78 cents per share, up 16.4% year over year. The figure surpassed the Zacks Consensus Estimate by 6.8%.
Revenues rose 13.6% to $1.74 billion and topped the consensus mark by 2.4%. Growth was driven by strong Transcatheter Aortic Valve Replacement (“TAVR”) demand and rapid adoption of the company’s mitral and tricuspid therapies.
Following the announcement yesterday, EW shares jumped nearly 3% in after-hours trading.
EW’s Segment Sales Reflect Broad-Based GrowthTAVR sales totaled $1.26 billion, up 11.3% year over year on a reported basis and 10.5% at constant currency. Growth was similar in the United States and international markets, supported by procedural momentum, clinical evidence favoring proactive treatment of severe aortic stenosis and continued adoption of the SAPIEN 3 Ultra RESILIA platform.
Transcatheter Mitral and Tricuspid Therapies (“TMTT”) sales reached $195.9 million, rising 47.3% year over year and 44.8% at constant currency. Double-digit growth in mitral and tricuspid procedures, increased adoption of PASCAL, the continued scaling of EVOQUE and the measured rollout of SAPIEN M3 drove the segment’s performance.
Surgical sales were $284 million, increasing 6.5% year over year and 5% at constant currency. Growth reflected continued adoption of RESILIA-based therapies, including INSPIRIS, MITRIS and KONECT. Edwards also received U.S. approval for ECLIPTIS and plans a measured rollout later in 2026.
Edwards’ Margins Reflect Earnings LeverageAdjusted gross margin was 77.6%, unchanged from the year-ago quarter. Foreign exchange created a 70 basis points (bps) headwind, which was offset by lower manufacturing expenses. Selling, general and administrative (SG&A) expenses increased to $561 million from $502 million, while research and development (R&D) expenses rose to $279 million from $276 million.
Adjusted operating income jumped 20.8% year over year to $522.7 million. The adjusted operating margin expanded 180 bps to 30%, supported by strong revenue growth and the planned timing of strategic investments in R&D and SG&A.
Edwards Maintains Financial FlexibilityAs of June 30, 2026, the company had approximately $2.90 billion in cash and cash equivalents. Total debt was about $600 million, leaving Edwards with substantial liquidity to support organic investment, manufacturing expansion and external opportunities in structural heart therapies.
The company also had roughly $1.50 billion remaining under its share-repurchase authorization. Management continues to prioritize growth investments before opportunistic capital returns.
EW Raises Sales Outlook and Reaffirms Earnings ViewEdwards increased its 2026 constant-currency sales growth guidance to 10-11% from the earlier 9-11%. Breaking it down, TAVR growth guidance was raised to 8-9% from 7-9%, while the TMTT sales outlook increased to $760-$780 million from $740-$780 million. Surgical sales are still expected to grow at a mid-single-digit rate.
Overall, EW now expects total sales of $6.60-$6.90 billion at current exchange rates. The Zacks Consensus Estimate for the same currently stands at $6.74 billion.
The company reaffirmed adjusted earnings guidance of $2.95-$3.05 per share despite expecting its tax rate to be at the high end of the prior 16-19% range. The Zacks Consensus Estimate for the metric is pegged at $3.00 at present.
For the third quarter of 2026, Edwards expects revenues of $1.63-$1.71 billion and adjusted earnings of 71-77 cents per share. The consensus mark for third-quarter revenues and earnings per share (EPS) is projected at $1.69 billion and 74 cents, respectively.
Our TakeEdwards exited the second quarter of 2026 with both earnings and revenues beating estimates. Performance reflected the strength of its comprehensive portfolio and agile execution, with growth supported by therapies across TAVR, mitral, tricuspid and surgical, as well as favorable contributions from each of the regions.
Within TAVR, Edwards’ competitive position in the United States is supported by continued adoption of its SAPIEN 3 Ultra RESILIA platform. TMTT benefited from the ongoing strong uptake of the PASCAL system. The expansion of adjusted operating margin in the quarter is also encouraging.
EW’s Zacks Rank and Key PicksEdwards currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Intuitive Surgical (ISRG - Free Report) , Danaher (DHR - Free Report) and Elevance Health (ELV - Free Report) .
Intuitive Surgical, carrying a Zacks Rank #2 (Buy), reported second-quarter 2026 adjusted EPS of $2.80, which surpassed the Zacks Consensus Estimate by 12.9%. Revenues of $2.89 billion beat the Zacks Consensus Estimate by 3.1%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
ISRG has an earnings yield of 3.1% compared to the industry’s negative 3% yield. The company beat earnings estimates in each of the trailing four quarters, the average surprise being 16.53%.
Danaher, carrying a Zacks Rank #2 at present, posted second-quarter 2026 adjusted EPS of $1.94, exceeding the Zacks Consensus Estimate by 5.44%. Revenues of $6.27 billion topped the Zacks Consensus Estimate by 2.88%.
DHR has an earnings yield of 4.7% compared with the industry’s 4.1% yield. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 5.65%.
Elevance Health, carrying a Zacks Rank #2 at present, posted second-quarter 2026 adjusted EPS of $7.45, exceeding the Zacks Consensus Estimate by 20.6%. Revenues of $49.8 billion outperformed the consensus mark by 0.8%.
ELV has an earnings yield of 6.9% compared to the industry’s 4.1% yield. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 5.65%.
Total Sales: $1.74 billion, a 12.5% increase year-over-year.Adjusted EPS: $0.78 for the quarter.TAVR Sales: $1.3 billion, a 10.5% increase over the prior year.
Edwards Lifesciences (EW - Free Report) reported $1.74 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 13.6%. EPS of $0.78 for the same period compares to $0.67 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $1.7 billion, representing a surprise of +2.45%. The company delivered an EPS surprise of +6.85%, with the consensus EPS estimate being $0.73.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Edwards Lifesciences performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Net Sales by Product Group- Transcatheter Mitral and Tricuspid Therapies: $198.6 million versus the four-analyst average estimate of $187.63 million. The reported number represents a year-over-year change of +47.7%.Net Sales by Product Group- Surgical Structural Heart: $284.1 million compared to the $277.73 million average estimate based on four analysts. The reported number represents a change of +6.5% year over year.Net Sales by Product Group- Transcatheter Aortic Valve Replacement: $1.26 billion versus the four-analyst average estimate of $1.23 billion. The reported number represents a year-over-year change of +11.3%.View all Key Company Metrics for Edwards Lifesciences here>>>
Shares of Edwards Lifesciences have returned -5.9% over the past month versus the Zacks S&P 500 composite's +0.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBHEdwards Lifesciences NYSE: EW reported stronger-than-expected second-quarter 2026 results, with management pointing to broad growth across transcatheter aortic valve replacement, transcatheter mitral and tricuspid therapies, and surgical products.
Chief Executive Officer Bernard Zovighian said the company delivered second-quarter sales growth of 12.5%, supported by “multiple therapies across TAVR, mitral, tricuspid, and surgical,” as well as contributions from each region. Total sales were $1.74 billion, and adjusted earnings per share were $0.78, according to Chief Financial Officer Doretta Mistras.
Get Edwards Lifesciences alerts:
Beyond Biotech—3 Healthcare Stocks for Growth-Minded InvestorsBased on the quarter’s performance, Edwards raised its full-year 2026 sales growth outlook for the total company, TAVR and TMTT while reaffirming its adjusted EPS guidance. The company now expects total company sales growth of 10% to 11%, up from 9% to 11%. It expects total company sales of $6.6 billion to $6.9 billion at current exchange rates. Adjusted EPS guidance remains $2.95 to $3.05.
TAVR Sales Beat Expectations Edwards reported global TAVR sales of $1.3 billion in the second quarter, up 10.5% from the prior year. Zovighian said the performance was stronger than expected and benefited from sustained clinical momentum, data supporting more proactive management of severe aortic stenosis, and continued adoption of the company’s SAPIEN platform.
3 Healthcare Pathbreakers With Long-Term TailwindsHe said TAVR growth rates were similar in the U.S. and outside the U.S. Average selling prices were stable globally. Growth also benefited from the exit of a competitor in the second quarter of 2025 and long-term durability data for SAPIEN, according to management.
Edwards raised its full-year TAVR sales growth guidance to 8% to 9%, from 7% to 9%. The company now expects TAVR sales of $4.75 billion to $5 billion at current exchange rates.
Zovighian said recent clinical presentations at the New York Valves Conference included a seven-year subanalysis supporting SAPIEN valve performance and durability, as well as a five-year analysis from the EARLY TAVR trial that added to evidence for treating aortic stenosis earlier in the disease pathway. He also said the first patients have been treated with the updated SAPIEN X4-S platform.
TMTT Growth Driven by Multiple Products Edwards’ transcatheter mitral and tricuspid therapies generated second-quarter sales of $195.9 million, up 44.8% year over year. Zovighian said PASCAL, EVOQUE and SAPIEN M3 all exceeded expectations in the quarter.
The company raised its full-year TMTT sales guidance to $760 million to $780 million, from $740 million to $780 million. Zovighian said the portfolio supports Edwards’ target of reaching $2 billion in TMTT revenue in 2030.
Management said PASCAL adoption continues to increase, citing physician interest in its design and clinical outcomes. Edwards expects next-generation PASCAL technology with Capture Clarity for mitral and tricuspid patients in the U.S. and Europe to be approved in the fourth quarter. The company also expects results from the Class II TR trial to be presented at TCT and plans a U.S. launch of PASCAL for tricuspid patients in the fourth quarter.
EVOQUE continues to scale in the U.S. and Europe, with Edwards expanding into new centers, increasing utilization at existing centers and working to streamline patient screening. Daveen Chopra, corporate vice president with responsibility for TMTT, surgical and IHFM, said EVOQUE is the second-largest TMTT platform by revenue after PASCAL and is “growing very quickly.”
For SAPIEN M3, Zovighian said early experience has validated the need for mitral replacement options for patients not well suited for mitral repair or surgery. Edwards received CE Mark for SAPIEN M3 RESILIA and broadened its indication for SAPIEN M3 and SAPIEN M3 RESILIA to include patients with mitral annular calcification.
Surgical Sales Rise 5% In surgical products, second-quarter global sales were $284 million, up 5% from the prior year. Zovighian said growth was driven by continued adoption of RESILIA-based therapies, including INSPIRIS, MITRIS and KONECT.
He also highlighted 10-year data from the COMMENCE trial presented at the AATS conference, saying the results showed favorable freedom from structural valve deterioration and a low rate of reoperation related to structural valve deterioration. Edwards also received U.S. approval for ECLIPTIS, its surgical left atrial appendage technology, and plans a measured rollout later this year.
The company continues to expect mid-single-digit sales growth in surgical in 2026.
Margins, Tax Rate and Third-Quarter Outlook Mistras said adjusted gross profit margin was 77.6% in the second quarter, flat from a year earlier, as foreign exchange headwinds were offset by lower manufacturing expenses. Foreign exchange reduced gross margin by 70 basis points compared with the prior year. The company now expects gross margin to be at the lower end of its full-year 78% to 79% guidance.
Second-quarter SG&A expense was $561 million, or 32% of sales, compared with $502 million a year earlier. R&D expense was $279 million, or 16% of sales, compared with $276 million, or 18% of sales, in the prior-year period. Edwards continues to expect R&D to be approximately 17% of sales in 2026.
Adjusted operating margin was 30% in the second quarter. Mistras said Edwards continues to expect full-year operating margin at the high end of its original 28% to 29% guidance, representing approximately 150 basis points of constant-currency operating margin expansion.
The company now expects its 2026 effective tax rate, excluding special items, to be at the high end of its prior 16% to 19% range, due to Pillar Two tax impacts and changes to California law limiting the use of R&D credits. GAAP EPS for the quarter was $0.42, primarily affected by the California R&D tax credit impact.
For the third quarter, Edwards projected sales of $1.63 billion to $1.71 billion and adjusted EPS of $0.71 to $0.77. Mistras said underlying growth in the third quarter will be “artificially lower” than first-half performance because the company faces a higher comparison from 2025, when seasonality had an unusually low impact.
Management Discusses NCD, PROGRESS Trial and Long-Term Growth During the question-and-answer session, analysts asked about TAVR growth drivers, the pending U.S. national coverage determination for TAVR, and the PROGRESS trial in moderate aortic stenosis.
Dan Lippis, Edwards’ global leader of TAVR, said the company is encouraged by the draft CMS policy and expects a final policy memo in September. He said potential benefits include a pathway for coverage of asymptomatic indications, recognition of symptomatic severe aortic stenosis as reasonable and necessary for Medicare beneficiaries without coverage with evidence development, and modernization of the policy to support heart teams in providing timely access to care.
On PROGRESS, Zovighian said Edwards separated the baseline characteristics presentation from the full results presentation to give physicians more time to understand the patient population. Lippis said the trial studies moderate aortic stenosis patients with at least one at-risk feature and emphasized that it is “not a heart failure trial.” Results are expected to be presented at TCT later this year.
Zovighian said the company expects minimal impact from PROGRESS in 2026 and reiterated that Edwards’ long-term TAVR outlook remains mid- to high-single-digit growth. He said the company remains confident in its target of approximately 10% average annual total company sales growth over the long term, alongside operating margin expansion.
About Edwards Lifesciences (NYSE:EW)Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Edwards Lifesciences Right Now?Before you consider Edwards Lifesciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edwards Lifesciences wasn't on the list.
While Edwards Lifesciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2026. Highlights Q2 sales grew 13.6% to $1.74 billion1, constant currency2 sales grew 12.5% Q2 TAVR sales grew 11.3% to $1.26 billion1; constant currency2 sales grew 10.5% Q2 TMTT sales were $195.9 million1,3, driven by portfolio of repair and replacement therapies Q2 EPS of $0.421; adjusted2 EPS of $0.781 Recent clinical data at New York Valves reinforce best-in-clas.
Information in Investor’s Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicitation, or rating to buy or sell securities. The information has been obtained from sources we believe to be reliable, but we make no guarantee as to its accuracy, timeliness, or suitability, including with respect to information that appears in closed captioning. Historical investment performances are no indication or guarantee of future success or performance. Authors/presenters may own the stocks they discuss. We make no representations or warranties regarding the advisability of investing in any particular securities or utilizing any specific investment strategies. Information is subject to change without notice. For information on use of our services, please see our Terms of Use.
*Real-time prices by Nasdaq Last Sale. Real-time quote and/or trade prices are not sourced from all markets. Ownership data provided by LSEG and Estimate data provided by FactSet.
IBD, IBD Digital, IBD Live, IBD Weekly, Investor's Business Daily, Leaderboard, MarketDiem, MarketSurge and other marks are trademarks owned by Investor's Business Daily, LLC.
The medical-technology company said it now expects sales of $6.6 billion to $6.9 billion for the full year, raising the bottom end of its prior range of $6.5 billion to $6.9 billion.
CompaniesJuly 23 (Reuters) - Edwards Lifesciences (EW.N), opens new tab beat analysts' estimates for second-quarter profit and revenue on Thursday, helped by strong demand for its artificial heart valves used in complex cardiac procedures, sending its shares up nearly 7% in extended trading.
Medical technology firms are seeing increased demand for surgical and procedural devices as population ages and healthcare needs grow.
Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
Here are some details:
Sales of Edwards' transcatheter aortic valve replacement device (TAVR) rose 11.3% over the year earlier to $1.26 billion during the quarter. Analysts on average estimated $1.23 billion, according to data compiled by LSEG.
TAVR is used to treat severe aortic stenosis, a condition where the aortic valve narrows and restricts blood flow from the heart.
Edwards raised the lower end of 2026 sales growth forecast for TAVR devices to 8% from 7% earlier, while keeping the upper end intact at 9%.
The company maintained annual adjusted profit expectations in the range of $2.95 to $3.05 per share.
The California-based company reported quarterly revenue of $1.74 billion, while analysts estimated $1.70 billion.
On an adjusted basis, Edwards earned 78 cents per share, compared with the estimate of 74 cents.
Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Shilpi Majumdar
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Andra AP fonden boosted its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW – Free Report) by 283.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 114,969 shares of the medical research company’s stock after acquiring an additional 84,969 shares during the quarter. Andra AP fonden’s holdings in Edwards Lifesciences were worth $9,207,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. MV Capital Management Inc. purchased a new stake in Edwards Lifesciences during the fourth quarter worth about $26,000. Hanson & Doremus Investment Management acquired a new position in shares of Edwards Lifesciences in the first quarter valued at approximately $25,000. Kemnay Advisory Services Inc. purchased a new stake in Edwards Lifesciences during the 4th quarter worth approximately $27,000. JPL Wealth Management LLC acquired a new stake in Edwards Lifesciences during the 3rd quarter worth approximately $25,000. Finally, Hilton Head Capital Partners LLC purchased a new position in Edwards Lifesciences in the 4th quarter valued at approximately $28,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.
Edwards Lifesciences Trading Down 0.7% NYSE EW opened at $84.41 on Wednesday. The firm’s fifty day moving average price is $87.60 and its 200 day moving average price is $83.91. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $96.29. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. The company has a market capitalization of $48.61 billion, a price-to-earnings ratio of 44.90, a price-to-earnings-growth ratio of 2.13 and a beta of 0.86.
Edwards Lifesciences (NYSE:EW – Get Free Report) last issued its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The company had revenue of $1.65 billion for the quarter, compared to the consensus estimate of $1.60 billion. During the same period last year, the firm posted $0.64 EPS. Edwards Lifesciences’s revenue for the quarter was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, sell-side analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.
Analysts Set New Price Targets EW has been the topic of several analyst reports. TD Cowen reiterated a “buy” rating on shares of Edwards Lifesciences in a research note on Tuesday. Royal Bank Of Canada upped their target price on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. BTIG Research raised their target price on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. Wall Street Zen downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Finally, Canaccord Genuity Group set a $85.00 price target on shares of Edwards Lifesciences and gave the stock a “hold” rating in a report on Friday, April 24th. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and an average target price of $98.95.
Get Our Latest Stock Analysis on EW
Insider Buying and Selling at Edwards Lifesciences In related news, VP Donald E. Bobo, Jr. sold 23,145 shares of the stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the sale, the vice president directly owned 98,611 shares of the company’s stock, valued at approximately $8,521,962.62. This represents a 19.01% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Daniel J. Lippis sold 619 shares of the firm’s stock in a transaction on Friday, July 10th. The stock was sold at an average price of $91.70, for a total value of $56,762.30. Following the transaction, the vice president directly owned 40,034 shares of the company’s stock, valued at $3,671,117.80. The trade was a 1.52% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 45,577 shares of company stock valued at $3,855,527. 0.31% of the stock is owned by corporate insiders.
Edwards Lifesciences Company Profile (Free Report)
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
Further Reading Five stocks we like better than Edwards Lifesciences Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINECalifornia Public Employees Retirement System Buys 44,533 Shares of Entegris, Inc. $ENTG
NEXT HEADLINE »California Public Employees Retirement System Sells 7,774 Shares of Global Payments Inc. $GPN
Key Takeaways EW is set to report Q2 2026 results on July 23, with revenues expected to rise 10.9% year over year.Edwards' TAVR growth may be aided by SAPIEN demand, clinical evidence and European guideline support.Edwards' TMTT and Surgical may have benefited from EVOQUE, SAPIEN M3, PASCAL and RESILIA therapy demand. Edwards Lifesciences Corp. (EW - Free Report) is scheduled to report second-quarter 2026 results on July 23, after the market closes.
In the last reported quarter, the company’s adjusted earnings per share (EPS) of 78 cents beat the Zacks Consensus Estimate by 4%. Its earnings topped estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 4.79%.
Edwards' Q2 EstimatesThe Zacks Consensus Estimate for the company’s second-quarter 2026 revenues is pegged at $1.70 billion, suggesting 10.9% growth from the year-ago reported figure.
The Zacks Consensus Estimate for second-quarter 2026 net earnings of 73 cents per share indicates a 9% increase from the year-ago reported figure. The estimate has remained unchanged in the past 60 days.
Factors Likely to Influence EW’s Q2 ResultsTranscatheter Aortic Valve Replacement (TAVR)In the second quarter of 2026, the TAVR segment is likely to have maintained its momentum, aided by procedural growth amid a heightened clinical focus on proactive disease management of severe aortic stenosis. Long-term clinical evidence supporting the SAPIEN platform’s durability and valve performance may have been a key driver.
Edwards may have continued to see strong sales of the SAPIEN 3 Ultra RESILIA valve across the United States and international markets, including Japan. In Europe, continued commercial execution and sustained physician demand for the SAPIEN platform are expected to have supported performance. The company may have continued to benefit from the exit of a competitor in the prior year.
Updated guidelines from the European Society of Cardiology and the European Association for Cardiothoracic Surgery, endorsing the role of TAVR for a broader patient population, may have positively influenced the segment’s performance.
The Zacks Consensus Estimate expects TAVR revenues to grow 9.1% year over year in the second quarter.
Transcatheter Mitral and Tricuspid Therapies (TMTT)Within TMTT, Edwards’ ongoing strength in the portfolio of repair and replacement therapies to treat mitral and tricuspid diseases is expected to have resulted in solid top-line growth. The EVOQUE tricuspid valve replacement system is likely to have continued to gain traction in both the United States and Europe.
Last year, the FDA approval of the SAPIEN M3 mitral valve replacement system marked a major milestone as the first transcatheter therapy utilizing a transseptal approach. Edwards’ early commercial experience has reflected the need for this mitral replacement solution for patients for whom mitral TEER is not an appropriate treatment option.
Favorable physician feedback on patient outcomes and procedural experience is likely to have continued to support the system’s adoption in the second quarter. Demand for the PASCAL transcatheter edge-to-edge repair system may have continued to expand, driven by physician interest in its differentiated design and clinical outcomes, as well as the significant unmet need among these patients.
The Zacks Consensus Estimate expects TMTT revenues to grow 39.3% year over year in second-quarter 2026.
Surgical Structural HeartThe segment’s second-quarter performance is likely to have benefited from the continued demand for Edwards’ RESILIA therapies. The global adoption of the INSPIRIS aortic valve is expected to have remained strong, while the KONECT tissue valved conduit is likely to have continued to gain traction following its European launch. The rollout of the MITRIS valve across more international markets may have supported growth in surgical mitral valve replacement procedures.
With Edwards maintaining its outlook for mid-single-digit Surgical sales growth in 2026, the second quarter is likely to have seen continued progress toward that target.
The Zacks Consensus Estimate anticipates Surgical revenues to grow 4.1% year over year.
Earnings Whispers for EdwardsPer our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates, which is not the case here, as you can see below:
Earnings ESP: Edwards has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
MedTech PicksHere are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time:
Labcorp (LH - Free Report) has an Earnings ESP of +0.71% and a Zacks Rank #2. The company is slated to release second-quarter 2026 results on July 30.
LH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 3.31%. The Zacks Consensus Estimate expects the company’s second-quarter EPS to increase 10.1% from the year-ago quarter’s figure.
Henry Schein (HSIC - Free Report) has an Earnings ESP of +0.41% and a Zacks Rank #2. The company is expected to release second-quarter 2026 results soon.
HSIC’s earnings surpassed estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.74%. The Zacks Consensus Estimate for the company’s second-quarter EPS calls for a rise of 10.9% from the year-ago quarter’s figure.
Alcon (ALC - Free Report) has an Earnings ESP of +3.13% and a Zacks Rank #2. The company is slated to release second-quarter 2026 results on Aug. 10.
ALC’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.66%. The Zacks Consensus Estimate anticipates the company’s second-quarter EPS to increase 1.3% from the year-ago quarter’s figure.
Boston Common Asset Management LLC increased its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW – Free Report) by 4.5% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 156,297 shares of the medical research company’s stock after purchasing an additional 6,744 shares during the quarter. Boston Common Asset Management LLC’s holdings in Edwards Lifesciences were worth $12,516,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Hanson & Doremus Investment Management bought a new stake in Edwards Lifesciences during the 1st quarter worth about $25,000. JPL Wealth Management LLC bought a new position in shares of Edwards Lifesciences in the 3rd quarter valued at about $25,000. MV Capital Management Inc. bought a new position in shares of Edwards Lifesciences in the 4th quarter valued at about $26,000. Kemnay Advisory Services Inc. acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at about $27,000. Finally, Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at about $28,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling at Edwards Lifesciences In other Edwards Lifesciences news, VP Daniel J. Lippis sold 619 shares of the company’s stock in a transaction on Friday, July 10th. The shares were sold at an average price of $91.70, for a total value of $56,762.30. Following the transaction, the vice president directly owned 40,034 shares in the company, valued at $3,671,117.80. The trade was a 1.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the completion of the transaction, the vice president directly owned 98,611 shares in the company, valued at $8,521,962.62. The trade was a 19.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 45,577 shares of company stock valued at $3,855,527 in the last quarter. 0.31% of the stock is currently owned by insiders.
Analyst Ratings Changes EW has been the subject of a number of analyst reports. BTIG Research raised their price target on Edwards Lifesciences from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Tuesday, June 30th. Truist Financial upped their price objective on Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “hold” rating in a research note on Thursday. Wall Street Zen cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. TD Cowen restated a “buy” rating and set a $104.00 target price (up from $97.00) on shares of Edwards Lifesciences in a report on Tuesday, June 2nd. Finally, Citigroup upped their price target on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat, Edwards Lifesciences has a consensus rating of “Moderate Buy” and an average target price of $98.95.
Read Our Latest Report on Edwards Lifesciences
Edwards Lifesciences Price Performance NYSE:EW opened at $85.72 on Monday. Edwards Lifesciences Corporation has a 12-month low of $72.30 and a 12-month high of $96.29. The firm has a market capitalization of $49.36 billion, a price-to-earnings ratio of 45.60, a P/E/G ratio of 2.15 and a beta of 0.86. The stock’s 50 day moving average price is $87.34 and its two-hundred day moving average price is $83.92. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06.
Edwards Lifesciences (NYSE:EW – Get Free Report) last issued its earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.73 by $0.05. The company had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The firm’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.64 EPS. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.
About Edwards Lifesciences (Free Report)
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
Featured Articles Five stocks we like better than Edwards Lifesciences Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit Shopify’s Quiet AI Strategy Could Be Its Biggest Advantage Yet Why These 3 Nuclear ETFs Are Getting a Fresh Look as AI Power Demand Rises 3 Aerospace Suppliers That Could Benefit as Aircraft Makers Face Bottlenecks Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW – Free Report).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEBoston Common Asset Management LLC Has $10.77 Million Position in Gilead Sciences, Inc. $GILD
NEXT HEADLINE »Cantillon Capital Management LLC Sells 1,451,818 Shares of Applied Materials, Inc. $AMAT
Diversify Wealth Management LLC reduced its position in shares of Edwards Lifesciences Corporation (NYSE:EW – Free Report) by 91.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,910 shares of the medical research company’s stock after selling 42,906 shares during the period. Diversify Wealth Management LLC’s holdings in Edwards Lifesciences were worth $318,000 at the end of the most recent quarter.
Other large investors have also modified their holdings of the company. MV Capital Management Inc. acquired a new stake in shares of Edwards Lifesciences in the 4th quarter worth $26,000. Hanson & Doremus Investment Management purchased a new position in shares of Edwards Lifesciences during the 1st quarter worth $25,000. Kemnay Advisory Services Inc. acquired a new position in shares of Edwards Lifesciences during the 4th quarter valued at about $27,000. JPL Wealth Management LLC acquired a new position in shares of Edwards Lifesciences during the 3rd quarter valued at about $25,000. Finally, Hilton Head Capital Partners LLC purchased a new stake in shares of Edwards Lifesciences in the fourth quarter valued at about $28,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.
Insiders Place Their Bets In related news, SVP Andrew M. Dahl sold 568 shares of the firm’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the sale, the senior vice president owned 15,334 shares of the company’s stock, valued at $1,319,950.72. This trade represents a 3.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the business’s stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the transaction, the vice president owned 98,611 shares of the company’s stock, valued at $8,521,962.62. This trade represents a 19.01% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 45,577 shares of company stock worth $3,855,527 in the last quarter. 0.31% of the stock is owned by company insiders.
Edwards Lifesciences Stock Performance NYSE EW opened at $85.72 on Friday. The company has a market cap of $49.36 billion, a P/E ratio of 45.60, a P/E/G ratio of 2.15 and a beta of 0.86. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. The stock has a 50-day moving average of $87.34 and a two-hundred day moving average of $83.94. Edwards Lifesciences Corporation has a 1-year low of $72.30 and a 1-year high of $96.29.
Edwards Lifesciences (NYSE:EW – Get Free Report) last posted its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.73 by $0.05. The business had revenue of $1.65 billion during the quarter, compared to analyst estimates of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The business’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current year.
Analyst Upgrades and Downgrades EW has been the topic of a number of analyst reports. Wall Street Zen downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday, July 4th. Citigroup increased their price target on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a research note on Wednesday, July 8th. BTIG Research raised their price target on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Mizuho upped their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the company an “outperform” rating in a report on Wednesday. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Monday, April 20th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $98.95.
Check Out Our Latest Stock Report on Edwards Lifesciences
Edwards Lifesciences Profile (Free Report)
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
Read More Five stocks we like better than Edwards Lifesciences Netflix May Be Cheap Enough to Tempt Buyers After Earnings Drop Delta vs. United: Which Airline Is Better Built for Higher Fuel Costs? The Market Sold Alcoa After Earnings—But It May Be Missing the Real Story Why Intuitive Surgical’s Strong Quarter Still Spooked Investors Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW – Free Report).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEFifth Third Bancorp Increases Stock Position in Powell Industries, Inc. $POWL
NEXT HEADLINE »ANB Bank Acquires Shares of 10,345 Netflix, Inc. $NFLX
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2026 after the market closes on Thursday July 23, and will host a conference call at 5:00 p.m. ET that day to discuss those results.
To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at ir.edwards.com.
About Edwards Lifesciences
Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Discover more at www.edwards.com and follow us on LinkedIn, Facebook, Instagram and YouTube.
Edwards, Edwards Lifesciences, and the stylized E logo are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Shareholders should contact the firm immediately as there may be limited time to enforce your rights.
, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Edwards Lifesciences Corporation (NYSE: EW) breached their fiduciary duties to shareholders.
If you currently own Edwards stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected].
Why Your Participation Matters:
Shareholder involvement can help improve a company's policies, practices, and oversight mechanisms to create a more transparent, accountable, and effectively managed organization, which can enhance shareholder value.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Halper Sadeh LLC
One World Trade Center
85th Floor
New York, NY 10007
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com
NEW YORK--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new data presented at New York Valves 2026, the annual conference organized by the Cardiovascular Research Foundation, which reinforce the company's leadership in advancing high-quality scientific evidence and innovating for patients. These new data – spanning aortic, mitral and tricuspid therapies – provide further understanding of the complexity of structural heart disease and the need for innovative treatment options.
Ahead of the planned full clinical presentation at TCT later this year, the baseline characteristics of the PROGRESS trial presented today provide new insights into the heterogeneous nature of moderate aortic stenosis (AS) patients. Research has shown that approximately half of moderate AS patients present with at least one at-risk feature, which includes symptoms, progressive cardiac damage, declining health and elevated risk of hospitalization. The PROGRESS trial is designed to evaluate whether patients with moderate AS and at least one risk factor may benefit from transcatheter aortic valve replacement (TAVR) earlier than current guidelines, which recommend clinical surveillance with echocardiographic follow-up every 1-2 years. Details of the PROGRESS trial design were recently published in the American Heart Journal and baseline characteristics of the PROGRESS trial are listed below:
More than 95% were symptomatic More than 70% had 2 or more at-risk features More than 90% had a normal left ventricular function Mean age was 78 ± 6 years Mean KCCQ score was 64 ± 24 Broad surgical risk distribution (46% low risk) Additional late-breaking clinical science presentations strengthen the evidence base for the SAPIEN 3 platform, including seven-year benchmark durability data from the PARTNER 3 trial, simultaneously published in JAMA Cardiology. Also presented were new findings from the EARLY TAVR trial, reinforcing the shift toward proactive disease management and providing continued long-term reassurance for physicians and patients. These data on Edwards’ SAPIEN platform underscore the benchmark valve performance and differentiated long-term durability of the therapy.
“Edwards remains focused on addressing the significant unmet needs of the many structural heart patients who remain untreated today,” said Bernard Zovighian, Edwards’ CEO. “Our expanding evidence base reflects Edwards’ clear and sustained commitment to advancing care through partnership with the physician community. From building a deeper understanding of the moderate AS population and advancing evidence about asymptomatic patients to demonstrating distinguished SAPIEN platform durability and strategies for lifetime disease management, we are strengthening confidence in long-term outcomes and increasing access for patients worldwide.”
Also at the meeting, new data highlighted clinical trial and real-world outcomes across Edwards’ mitral and tricuspid portfolio. Data from more than 4,500 patients treated with the PASCAL system in the STS/ACC Transcatheter Valve Therapy Registry helps highlight the sustained safety and effectiveness of the technology for patients with mitral regurgitation (MR). One-year data from the ENCIRCLE trial Mitral Annular Calcification (MAC) Registry support the safety, effectiveness and quality of life improvements with SAPIEN M3, the first and only transcatheter transseptal mitral valve replacement system, in patients with symptomatic valve dysfunction associated with MAC who are deemed unsuitable for surgery or TEER therapy by a heart team.
Zovighian added, “Together, our differentiated technology and world-class evidence reflect Edwards’ leadership in elevating the standard of care for structural heart patients and improving outcomes across the care continuum.”
About Edwards Lifesciences
Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Discover more at www.edwards.com and follow us on LinkedIn, Facebook, Instagram and YouTube.
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, but are not limited to, statements made by Mr. Zovighian and statements regarding the benchmark performance and differentiated long-term durability of Edwards’ SAPIEN platform, elevating the standard of care, our leadership in advancing our growing body of high-quality scientific and clinical evidence, long-term reassurance for physicians and patients, our commitment to advance care through partnerships with the physician community, strengthen confidence in long-term outcomes and expanding access for patients, innovating for patients with structural heart disease, the safety and effectiveness and quality of life improvements of our products, and improving outcomes across the care continuum, and other statements that are not historical facts. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. Investors are cautioned not to unduly rely on such forward-looking statements.
Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those expressed or implied by the forward-looking statements based on a number of factors as detailed in the company's filings with the Securities and Exchange Commission. These filings, along with important safety information about our products, may be found at Edwards.com.
Edwards, Edwards Lifesciences, the stylized E logo, EARLY TAVR, ENCIRCLE, PARTNER, PARTNER 3, PASCAL, PROGRESS, SAPIEN, SAPIEN 3 and SAPIEN M3 are trademarks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.
